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CK2 negatively regulates 5-HT4 receptor signaling in the prefrontal cortex and mediates depression-like
behaviors
by
Julia Castello Saval

Abstract

Advisor: Dr. Eitan Friedman

The serotonergic system has been the major candidate in the pathophysiology of mood related disorders
such as anxiety and major depressive disorder (MDD). Unfortunately, current antidepressant drugs are
ineffective in 50% of the population and require chronic administration for a period of 3-6 weeks before the
onset of therapeutic response. 5-HT4 receptor (5-HT4R) agonists have emerged as potential candidates
for fast antidepressant action, since an antidepressant response can be achieved after 3 days of
pharmacological administration in rodents.
This dissertation aims to investigate the role of casein kinase 2 (CK2) as a regulator of 5-HT4R expression
and activity using in vitro techniques and in vivo mouse models. We present evidence, in two different CK2α
conditional knockout (KO) mouse lines, that CK2 regulation of 5-HT4R is region specific in the brain. When
CK2α is ablated, 5-HT4R mRNA expression is upregulated in the medial PFC (mPFC) but not in other
regions where CK2α is also absent like the striatum or the hippocampus. In vitro, 5-HT4R signaling and
expression at the plasma membrane is enhanced after shRNA knockdown or pharmacological inhibition of
CK2. In vivo, 5-HT4R is also upregulated as evidenced by increased pERK expression in the mPFC that is
sensitive to 5-HT4R antagonist treatment, GR113808, of the CK2α KO mice. Behaviorally, the CK2α KO
mice present an antidepressed and anxiolytic-like phenotype in a battery of tests of behavioral despair and
they are more sensitive to antidepressant treatment when compared to wild-type (WT) littermates.
Interestingly, AAV9-mediated knockdown of CK2α in the mPFC of adult mice is sufficient to phenocopy the
behavior of the CK2α KO animals. Although AAV9-HTR4-shRNA-mediated reduction of HTR4 expression
in the mPFC of CK2α lead only to partial rescue of the phenotype, it was sufficient to overexpress 5-HT4R
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in the mPFC to generate mice with an antidepressed- and an anxiolytic- like behavior. In addition, AAV9mediated knockdown of CK2α but not 5-HT4R overexpression lead to increased neurogenesis in the ventral
hippocampus. This was paralleled by an impairment in spatial learning and indicated that while the CK2mediated regulation of 5-HT4R is specific to the mPFC and responsible for the antidepressed and anxiolyticlike phenotype, CK2 might also act through a 5-HT4R-independent mechanism responsible to act on
aspects of cognition and neurogenesis.
In summary, my work identifies CK2 as a region-specific negative regulator of 5-HT4R levels and activity
and provides evidence that manipulation of CK2 through the upregulation of the 5-HT4R is responsible for
mood-related phenotypes and provides a new mechanism of antidepressant action.
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Chapter 1
Introduction
Adapted from the 2018 publication: Heike Rebholz, Eitan Friedman and Julia Castello. “Alterations of
expression of the serotonin 5-HT4 receptor in brain disorders” Internationa Journal of Molecular Sciences
(2018) 19(11), 3581

1.1 Major depressive disorder
Major depressive disorder (MDD) affects 17% of the US population. According to the World Health
Organization, 450 million people worldwide suffer from the disease and it is predicted to be the leading
cause of disability by 20301. Depression is rare in children and sex differences emerge during adolescence.
In adolescents and adults, females are twice more at risk than males2,3
The most common MDD symptoms, according to the Diagnostic and Statistical manual of Mental Disorders
5 (DSM V) are sadness, feelings of emptiness or hopelessness throughout most of the day; anhedonia
(which refers to the inability of experiencing pleasure), irritability, weight loss or weight gain, increased or
decreased appetite, abnormal sleep (insomnia or hypersomnia), agitation or fatigue, loss of energy, low
self-esteem, excessive guilt, inability to focus as well as impaired decision making and ultimately, suicidal
thoughts. An individual presenting 5 of these symptoms nearly everyday is diagnosed with MDD meaning
that there are a total of 227 possibilities to meet the symptom criteria for MDD 4 and due to the large
heterogeneity of the disease, its study becomes very challenging.
MDD is often preceded by long-term anxiety and it comes to no surprise that 60% of the patients suffering
from MDD present comorbidity with anxiety disorders 5 sharing both emotional negative states and over
activation of the same neural circuits like amygdala and anterior cingulate cortex6. In normal conditions,
anxiety states are helpful in identifying threat7: transient rise in cortisol levels triggers the fight-or-flight
response, boosts energy levels and improves confidence but dysregulation of cortisol levels by over activity
of the hypothalamic-pituitary-adrenal axis (HPA axis) can lead to chronic stress and an overestimation of
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threat, that can ultimately cause depression8,9. The consequences of sustained stress are hippocampal
atrophy, which include retraction of dendritic neurons, inhibition of neurogenesis and loss of preformed
adult hippocampal neurons altogether resulting in a loss of hippocampal volume. These neurological
degradations have become key neurological markers in MDD10-12.
1.2. Treatment of Major Depressive Disorder
Cognitive behavioral therapy or psychotherapy can be effective in treating mild depression but
antidepressant drugs are needed for MDD. In cases where pharmacological administration is not effective
or the patient is too debilitated, electroconvulsive treatment can provide an acute effective response13,14 but
the side effects include partial memory impairment and retrograde amnesia 15. As an alternative, targeted
stimulation like deep brain stimulation and transcranial magnetic stimulation can ameliorate the symptoms
of depression16.
Nowadays, the most prescribed antidepressant drugs to treat MDD act on the monoaminergic system
comprised of the three neurotransmitters: serotonin (5-HT), dopamine (DA) and norepinephrine (NE). The
first generation of antidepressant drugs are monoamine oxidase inhibitors (MAOI) and tricyclic
antidepressant (TCA) drugs. MAOIs were discovered by serendipity in 1951 17. MAOI impair the ability of
the MAO enzyme to breakdown 5-HT, DA and NE. TCAs include imipramime, amitriptyline, desipramine
and cloropramine and their mechanism of action is by blockade of serotonin and/or norepinephrine
transporters18. Both MAOI and TCA increase the availability of monoamines at the presynaptic terminal.
First generation antidepressants are rarely prescribed due to its strong side effects including memory and
cognitive deficits, blurry vision, dizziness, mouth drying, urinary retention and hypotension in TCA19 and
withdrawal symptoms, dietary restrictions and toxicity with risk of overdose in MAOI 20.
The second generation of antidepressant drugs are selective serotonin reuptake inhibitors (SSRIs) and are
the most commonly used worldwide. They are prescribed to treat depression and anxiety disorders and, in
high doses, obsessive-compulsive disorder21. They include citalopram, escitalopram, fluoxetine,
vilazodone, sertraline and paroxetine. They work by blockade of the serotonin transporter (SERT) inhibiting
the reuptake of serotonin into the presynaptic terminal thus, enhancing serotonin levels at the synapse and
increasing neurotransmission21,22. This mechanism can be understood as an indirect agonism of serotonin
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receptors. Despite the amelioration of the side effects, SSRIs fail to be more effective than the first
generation antidepressant drugs and are only successful in one third of the population23. Furthermore, their
delayed onset of action of three to six weeks exposes a severe clinical problem 24 since patients might
experience frustration due to the lack of improvement in early phases of treatment leading to fatal
consequences like increased suicidal thoughts. In addition, relapse might occur once treatment is ceased25.
Therefore, there is an urgent need for alternative treatments with rapid onset of action.
1.3. Etiology of Major depressive disorder
MDD is caused by a combination of environmental, genetic heterogeneity and neurological factors. The
cathecholamine hypothesis26 and the later serotonin hypothesis formulated by Coppen27 phrased that
depression is triggered by a lack of serotonin in the brain and can be reversed by an increase of serotonin
levels. Although this statement is nowadays simplistic, the serotonergic system has remained the focus of
attention in the understanding of MDD. Decreased 5-HT transmission correlates with MDD 28, and this
function is restored after antidepressant treatment29. In addition, depressed patients present lower levels
of plasma tryptophan30, a 5-HT precursor, and lower levels of 5-H1AA, a 5-HT metabolite, in the
cerebrospinal fluid29. Also, they show a blunted inhibitory hormonal response when they confront a
serotonergic challenge and a decreased serotonergic response in the brain31.
Despite the correlation between MDD and the serotonergic system dysfunction, it is imperative to clearly
understand the etiology of the disease in order to identify new targets that can overcome the lack of
efficiency of SSRIs as well as their delayed onset of action.
1.4 The serotonergic system
The serotonergic system is comprised of 250 000 neurons out of 10 11 total neurons in the human brain
creating the second largest population of neurons after the glutamate network 32. The largest nucleus of
serotonergic neurons originates from the dorsal raphe nucleus (DRN), located in the brainstem.
Serotonergic neurons are larger than any other cells and have cell bodies with axons projecting throughout
the whole brain and spinal cord creating a complex network regulated by several different mechanisms 33.
Changes in serotonergic neurons influence a wealth population of neurons in the forebrain by: glutamatergic
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inputs from the PFC, noradrenergic inputs from the pontine nuclei, inhibitory GABA-ergic inputs from local
interneurons and dopaminergic inputs from the midbrain dopaminergic nuclei as well as self-regulation via
inhibition of 5-HT1A autoreceptors34.
1.5. Serotonin receptors and antidepressant action
Several 5-HT receptors have been discussed as mediators of antidepressant action. 5-HT1A autoreceptors
play a critical role for being a key component in the negative feedback loop of the DRN, where increased
5-HT will stimulate presynaptic 5-HT1A autoreceptors counteracting the effect of SSRIs35 (Image 1.1).
Interestingly, the time period required for antidepressant efficacy (3 to 6 weeks) coincides with the
timeframe necessary for 5-HT1A autoreceptor desensitization35. Supporting evidence show that patients
with increased density of 5-HT1A autoreceptors are more susceptible to suffer mood disorders and are less
responsive to antidepressants36,37. In postmortem and neuroimaging studies, increased density of 5-HT1A
autoreceptors in MDD patients is detected without change in postsynaptic 5-HT1A receptors38. In addition,
5-HT1A knockout (KO) mice show an antidepressed-like phenotype39. Chronic antidepressant treatment
increases hippocampal neurogenesis mediated through activation of 5-HT1A receptors in the dentate
gyrus40. Nevertheless, administration of 5-HT1A receptor agonist has not been more efficient than SSRIs.
This might be caused by the preferential activation of the presynaptic receptors thus, decreasing 5-HT firing
and release in addition of a low specificity towards targeting postsynaptic receptors 41. The contribution of
other 5-HT receptors to MDD and to the mechanism of action of antidepressants cannot be excluded and
is summarized in Table 1.
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Table 1.1. Summary of the most relevant 5-HT receptors and their in vivo outcomes in depression
and anxiety as reviewed in 42

5

1.6. The 5-HT4 receptor

The 5-HT4R has received significant attention in the context of MDD. 5-HT4R are G protein-coupled
receptors (GPCRs) coupled to Gαs. They are mainly located in the putamen, caudate nucleus, nucleus
accumbens, hippocampus, globus pallidus and substantia nigra and less predominantly in the neocortex,
raphe and pontine nuclei as well as some areas of the thalamus 43.
Firing of the DRN can be increased through administration of 5-HT4R agonists and significantly decreased
with 5-HT4R antagonists. Also, the 5-HT4R KO mice

44

present lower firing of serotonergic neurons in the

DRN. In particular, 5-HT4R overexpression in the medial pre frontal cortex (mPFC) has been shown to
enhance firing of DRN neurons, establishing 5-HT4R as a major player in the PFC-DRN positive feedback
loop (Image 1.1)45. Furthermore, chronic administration of 5-HT4R agonist enhanced 5-HT4R activity which
peaks after 3 days of treatment without undergoing desensitizatio thus keeping the positive feedback loop
intact over a prolonged period of time45 leading to increased synaptic 5-HT levels and desensitization of 5HT1A autoreceptors45. In addition, rats treated with partial agonist RS67333 showed increased postsynaptic 5-HT1A receptor function in hippocampal CA3 pyramidal cells, phosphorylation of cAMP response
element-binding (CREB) protein and neurogenesis in the hippocampus 46, common markers of
antidepressant action47.
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Image 3.1 Representation of the effects of SSRIs administration in the brain. Acute inhibition of SERT
causes endogenous 5-HT release. 5-HT1A and 5-HT1B autoreceptors are activated in the DRN and modulate
the firing rate of 5-HT neurons via the negative and positive feedback loops (blue and purple loops,
respectively). Autoinhibition/ Desensitization of 5-HT1B autoreceptors in the axon terminals also takes place.
5-HT1A and 5-HT4R in the PFC layer 5 pyramidal neurons modulate 5-HT firing by inhibiting and activating
in a long-feedback loop, respectively (blue and orange arrows).
Image source: Lutz PE. Multiple serotonergic paths to antidepressant efficacy. J Neurophysiol (2013)

Behaviorally, partial agonists RS67333 or SL650155 have been described as rapid acting antidepressant
drugs in preclinical rodent models of depression47-51. The therapeutic response to subchronic and chronic
administration of 5-HT4R agonists or fluoxetine in rodents to most depression and anxiety assessment tests
is independent of neurogenesis and only the novelty suppressed feeding test require hippocampal
neurogenesis in order to achieve the beneficial effects of antidepressants

51.

The behavioral effects of

fluoxetine are abolished when co-administered with the 5-HT4R antagonist GR125487 indicating that 5HT4R action is required to mediate the behavioral effects of fluoxetine46,51. 5-HT4R is upregulated in the
cortex after fluoxetine treatment and this upregulation is required for the behavioral effects 52. Taken all
together, targeting 5-HT4R could become a new alternative treatment with fast onset of action. In addition,
studies in humans show that patients with familial risk of depression and suicide exhibit reduced 5-HT4R
binding53, and 5-HT4R gene (HTR4) polymorphisms in the spliced variant region are associated with
unipolar depression54.
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1.7. Regulation of 5-HT4R expression
Surprisingly, little is known about the transcriptional regulation of the HTR4 across tissues. The HTR4
mRNA is transcribed from a very complex gene encompassing 38 exons spanning over 700 kb and multiple
C-terminal isoforms are expressed in specific tissues in the CNS

55.

To date, it is not known how 5-HT4R

expression is regulated in the brain, and so far we have only rudimentary knowledge about the promoter,
derived from human atrial tissue and placenta56,57. In the heart, the major transcription start site of the HTR4
gene is located at −3185 bp upstream of the first start codon 56. In placenta, the 5’-UTR is even longer,
spanning over 5100 bp upstream from the translation start site 57. The different 5’-UTRs upstream of the
translation initiation codon are interesting since they may hold an additional key to understand region and
cell-type specific regulation of protein expression. The promoter lacks TATA and CAAT canonical motifs,
but contains several transcription factor binding sites56. Interestingly, a short region of 200 bp was shown
to drive transcription in human cells but not in monkey cells, indicating that regulation is species-specific56.
These different transcriptional initiation sites might not alter the protein-coding region yet might alter the
extent and pattern of expression of 5-HT4R. It is hypothesized that such long 5’-UTR reduces RNA
translation and leads to low levels of expressed transcripts by causing premature initiation at a wrong ATG
and preventing the ribosome from reaching the correct start codon 58. In addition to the different lengths of
5’-UTR there also exist isoforms in the 3’-UTR regions that are targets for post-transcriptional modification
by non-coding RNAs such as miRNAs. For example, miR-16 and miR-103 downregulate 5-HT4R transcript
levels in vitro and it was found that patients with irritable bowel syndrome present in the gastrointestinal
track predominantly an isoform of 5-HT4R that lacks the binding sites for miR-16 and miR-10359. Let-7a is
another miRNA that can regulate 5-HT4R60.
There are at least 8 human 5-HT4R splice variants named a-d,g,h,I,n55,61-64. Isoforms a,b,c,g and n are
highly expressed in the CNS. Mice have five isoforms 65 known and rats have four64,66. To date, no specific
isoform has been linked to a brain disorder.
1.8. Post-translational regulation of 5-HT4R
Different post-translational regulation mechanisms of 5-HT4R have been described in several in vitro
studies. One of them is phosphorylation mediated endocytosis. G protein-coupled receptor kinases (GRKs)
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are able to phosphorylate GPCRs in their intracellular domains to initiate endocytosis 67. For example, GRK2
phosphorylates and desensitizes 5-HT4R resulting in lower cAMP/PKA pathway activation68 and GRK5
phosphorylates 5-HT4R activating ERK phosphorylation69.
Palmitoylation (where a lipidic cysteine group undergoes esterification with a palmitoyl group generating a
link to the lipid bilayer of the plasma membrane) allows for rapid regulation of protein function, affecting
GPCR endocytosis, phosphorylation, desensitization and ultimately, cellular signaling. The mouse 5-HT4R
a variant is pamitoylated at 3 highly conserved cysteine sites and at a C-terminal cysteine that is variantspecific. When palmitoylation takes place near protein-protein interaction motifs it will affect the binding
character of the receptor, constitutive activity or internalization.70,71
One study shows that the 5-HT4R has two putative N-linked sites susceptible of glycosylation, one in the
second extracellular loop and one at the N-terminus72.
What is clearly missing in our understanding of all described post-translational modifications are data
generated from physiologically expressed 5-HT4R such as in mouse brain, a comparison between brain
regions and an analysis in response to drug treatment or of mental disease models.
1.9. Regulators of the 5-HT4R
5-HT4R expression changes have been identified in rodent models of depression and anxiety such as
bulbectomy, glucocorticoid receptor heterozygous mice, social defeat stress or exposure to prenatal stress.
As well as in other neurological diseases like obesity, Alzheimer’s disease, schizophrenia and Parkinson’s
disease.
Very few proteins have been identified as regulators of 5-HT4R expression. One of them is SERT or 5-HTT.
Protein levels of 5-HT4R are altered in the 5-HTT KO and 5-HTT overexpressing mice. Precisely,
autoradiography studies with [3H]SB207145 radioligand showed increased 5-HT4R binding in the 5-HTT
OE mice in all brain regions but the amygdala. Inversely, in the 5-HTT KO mice, 5-HT4R binding is
decreased in all regions studied. This is consistent with studies providing evidence that chronic treatment
with SSRIs of healthy individuals decreased 5-HT4R binding through PET imaging73. Studies in rodents
replicate this result of decreased 5-HT4R-dependent activation of adenylate cyclase and reduced
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electrophysiological activity in the hippocampus 74. In a similar fashion, mice overexpressing 5-HT4R in the
mPFC exhibit stress-induced hypophagia and a corresponding 5-HT4R-dependent downregulation of SERT
and 5-HT1A transcripts75. Oppositely, siRNA mediated knockdown of 5-HT4R in the mPFC induces
hyperphagia75.
These studies are important because they highlight that altered 5-HT concentration is most likely
responsible for changes in 5-HT4R receptor binding as a compensatory mechanism as well as bidirectionality of this process, since exogenous alterations in 5-HT4R levels induce changes in 5-HT
availability negatively regulating the expression of SERT as well as other 5-HT receptors.
S100 calcium effector protein p11 (S100A10), a depression marker protein, has been identified in a yeastbased screening system as a binding partner of 5-HT4R, with greater affinity to 5-HT4R than to other
serotonin receptors, like 5-HT1B and 5-HT1D 76. p11 co-localizes with 5-HT4R in brain regions that play an
important role in MDD like cingulate cortex, hippocampus, amygdala and striatum as seen by in situ
hybridization and immunohistochemistry using transgenic bac-GFP mice where GFP is expressed under
the 5-HT4R promoter. p11 KO mice showed reduced 5-HT4R protein in radioligand binding assays, were
behaviorally less sensitive to antidepressant treatment and did not respond to 5-HT4R agonist. As binding
partner of 5-HT4R and adaptor protein for many other GPCRs, p11 recruits 5-HT4R to the site of its action,
the plasma membrane76.
Nav1.7 is a voltage-gated sodium channel required for nociceptive neuronal activation. While humans
lacking Nav1.7 and genetic KO mice show absence of pain, a pharmacological antagonist of the receptor
failed to decrease pain sensitivity, indicating that receptor-signaling-mediated activation of nociceptive
neurons might not be the only mechanism involved in pain alleviation. For example, loss of Nav1.7
coincided with upregulation of met-enkephalin, an endogenous opioid growth factor in sensory neurons,
increasing opioid activity and anti-nociceptive signaling. In addition, Nav1.7 KO mice presented reduced
levels of 5-HT4R in the dorsal root ganglia77. Both effects, changes in encephalin and 5-HT4R expression
and signaling, took place in peripheral nociceptive neurons and together contributed to the analgesic
effect78.
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We found a novel regulator of the 5-HT4R.

In the mouse brain there is a region-specific negative

transcriptional regulation exerted by CK2. CK2 is a constitutively active and ubiquitously expressed kinase
that targets a myriad of substrates. We have identified CK2 as a negative regulator of the 5-HT4R both at
the transcript level as well as the post-translational level. Conditional KO of the catalytic subunit of CK2,
CK2α, in the hippocampus, striatum and the cortex lead to an upregulation of 5-HT4R mRNA selectively in
the PFC79. Furthermore, in luciferase assays, using a 4 KB upstream element fused to luciferase cDNA,
expression was promoted when CK2 was inhibited or knocked down in HeLa cells but not in HEK293 or
COS7 cells, underlining the importance of tissue-specifically expressed transcription factors. Knockdown
or inhibition of CK2 in vitro, elevated 5-HT4R-dependent cAMP generation and increased receptor
localization at the plasma membrane. And in vivo, CK2 KO mice presented an elevated 5-HT4R dependent
pERK activation. Virally-mediated focal knockdown of CK2α or overexpression of 5-HT4R in the mPFC
generated an anti-depressed and anxiolytic-like phenotype that was similar to the phenotypes observed
with CK2α knockout in the forebrain driven by Emx1-Cre or Drd1a-Cre. In addition, such conditional CK2α
KO mice were more responsive to antidepressants and 5-HT4R agonist treatment.
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Chapter 2
Casein Kinase II structure and regulation in the brain
Adapted from 2017 publication: Julia Castello, Andre Ragnauth, Eitan Friedman and Heike Rebholz.
“CK2- an emerging target for Neurological and Psychiatric Disorders” Pharmaceuticals (2017) 10(1), 7

2.1. Introduction
2.1.1. Structure of CK2
Casein Kinase II (CK2) is a heterotetramic enzyme consisting in two catalytic subunits (α and/or α’) and
two regulatory subunits (β)80 (Image 2.1). It is constitutively active and ubiquitously expressed. CK2 is
found in the nucleus, the cytoplasm and the plasma membrane as well as in organelles like the Golgi
complex, the endoplasmatic reticulum and the ribosomes. CK2 activity is regulated through different
mechanisms including recruitment into multi-molecular complexes, interaction with other proteins and
changes in expression levels81. CK2 is a serotonin/threonine kinase that prefers phosphorylation of amino
acids located in acidic clusters82. The general consensus is that substrates require an acidic residue in
the position n+383,84. The minimal consensus sequence for phosphorylation by CK2 is Ser-XAA-XAA-Acidic;
where the acidic residue can be Glu, pSer, Asp or pTyr. For this reason, CK2 has less specificity than
other kinases, such as MEK, and phosohorylates more than 365 substrates in vitro 85 constituting 25% of
the phosphoproteome86. However, the number of real bona fide in vivo substrates is predicted to be much
lower87
CK2α and CK2α’ share 90% identity despite being products of different genes 88,89. Due to its enzymatic
similarities it has been challenging to differentiate which subunit is responsible for its phosphorylation
activity in vitro. The C-terminal domain is unique for each subunit and each of them are highly conserved
between species88.
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Image 4.1. Ribbon diagram of the crystal structure of human tetrameric CK2. PDB entry number
1JWH. Structure determined at 3.1 A resolution. Catalytic subunit CK2α is illustrated and in in yellow. The
two regulatory subunits CK2β are illustrated in blue.

2.2.2.

Regulatory mechanisms of CK2

2.2.2.1 Assembly/Disassembly of CK2
There are different hypotheses surrounding the regulative mechanisms of CK2. One of the main hypotheses
is that CK2 activity can be modified by regulated assembly and disassembly of the heterotetramer and even
tetramers of higher order. There is evidence from dynamic localization studies that, in the cell, CK2α and
CK2β can exist independently and that CK2α and CK2α´are able to phosphorylate specific substrates such
as calmodulin independently of CK2β. 9091
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2.2.2.2 Phosphorylation/Autophosphorylation
CK2 is constitutively active and does not require phosphorylation to be activated; nevertheless,
phosphorylation can partially contribute to its regulation. Mammalian cells have a number of
phosphorylation sites both in CK2α and CK2β92-94. CK2β undergo autophosphorylation at Ser2 and Ser3
close to the N-terminus 95 and can be phosphorylated in a cell cycle dependent manner at Ser20996. Instead,
CK2α is phosphorylated in a cell cycle-dependent manner at four different amino acidic residues in their Cterminal region and can engage in autophosphorylation at Tyr182, a site located in the activation loop in
absence of the β subunit97.
2.2.2.3 Small molecules
CK2 is permanently in an active conformation and does not depend on second messengers to get activated.
However, some small molecules like heparin can deactivate CK2 in vitro while polyamines, essential
molecules for cell growth and differentiation, can activate the kinase in vitro and in vivo to some extent.98,99
2.2.2.4 Protein-protein interactions
Proteins can interact with CK2 in different modes. For example, proteins can bind to CK2 and form a
molecular complex to increase their specificity of substrate- phosphorylation in vitro. Two examples of this
interaction are nucleolar proteins namely, Nopp140, that associates to CK2β, or nucleolin, that binds to
CK2α or CK2α’100,101. Fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) are able to modulate
autophosphorylation of CK2. In vitro, increasing concentrations of FGF-1 and FGF-2 bind to CK2β and
reduce its autophosphorylation102. Reduced autophosphorylation of CK2β is correlated with a slightly
decrease in activity103,102 .
CK2 interacts and phosphorylates Hsp90, a major molecular chaperone and phosphorylates Cdc37, a cochaperone, in vitro and in vivo104. Hsp20-Cdc37 complex is required for the correct folding and function of
proteins and CK2 phosphorylation of Cdc37 is essential for the function of the Hsp90-Cdc37 complex105 .
Finally, other proteins might mediate translocation of CK2 thus, altering the ability of CK2 to phosphorylate
certain targets; for example, Pin1 binds to CK2α blunting the ability of the kinase to phosphorylate
topoisomerase IIα106.
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2.2.3.

Functions of CK2

CK2 plays a critical role in cell proliferation, differentiation and apoptosis and it is overexpressed in many
cancers107. Interestingly, CK2 phosphorylates several components of the PI3 kinase-Akt pathway. Akt is an
important pro-survival kinase dysregulated in many cancers. For example, phosphorylation of Ser129 on
Akt activates the kinase108 while phosphorylation of Ser380/Thr382/Thr383 on PTEN inactivates the
phosphatase109. Thus, the net result of CK2 action is to positively regulate the PI3K-Akt survival pathway,
a finding which is underlined by the fact that incubating cells with CK2 pharmacological inhibitors lead to
apoptosis110
Given CK2’s abnormal expression/activity in cancer, both Akt and CK2 have received special attention as
possible targets in its treatment. Interestingly, the inhibitor CX4945 is under clinical trials (phase 2)
(ClinicalTrials.gov Identifier: NCT02128282). Recently, the non-competitive NMDA antagonist ketamine
has proven a fast and durable antidepressant effect possibly due to a rapid increase in synaptogenesis and
spine formation in the PFC via the PI3K-Akt-mTOR pathway as well as reversing dendrite atrophy caused
by stress111. Inhibition of CK2 causes inactivation of mTOR through the PI3K-Akt-mTOR pathway112.
2.2.4.

Role of CK2 in the central nervous system

CK2 expression is higher in the brain compared to other organs113 but its function in neurons is poorly
understood. Some brain substrates have been identified such as the glutamate receptor, NMDAR 114,115,
alpha-synuclein or synphilin-1116 and it has also been shown to phosphorylate certain brain-specific
transcriptional regulators, namely, the AUTS2-Polycomb complex that is often disrupted in neurological
disorders such as intellectual disability, developmental delay and autism spectrum disorders 117,118. Previous
studies show the implication of CK2 in neurological disease such as Glioblastoma multiforme (GBM), one
of the most aggressive human glial tumors comprising 15% of all brain tumors119. In GBM, CK2α levels are
quadruplicated compared to a healthy brain120. Inhibition of CK2 activity through small molecule inhibitors
or siRNA, induced apoptosis reducing growth in GBM cells in mouse xenograft models of human as well
as in mice that had been injected intracranially with human GBM tumors 121.
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Parkinson´s disease (PD) is the second most prevalent neurodegenerative disorder 122. CK2 is able to
phosphorylate α-synuclein at Ser129123 (a hallmark in PD) as well as synphilin, a binding partner of αsynuclein, altering their interaction116. In addition, previous work from our lab found evidence that CK2
modulates the brain’s response to dopamine depletion as well as to anti-parkinsonian treatment. We
showed that the activity of two major dopamine responsive neuronal cell types in the striatum, namely the
direct and indirect pathway spiny projection neurons, are modulated by lack of CK2, possibly via changes
in expression and plasma membrane availability of the dopamine D1 and the adenosine A2a
receptors124,125. Both receptors are key players in the behavioral responses to dopamine and L-DOPA. Our
lab found that ablation of CK2 in D1-receptor cells in a mouse model of PD alleviate L-DOPA induced
dyskinesia (LID). Instead, depleting CK2 from D2- receptor cells aggravate the formation of LIDs. These
findings suggest a major role of CK2 in the signaling involved in LID in the two main striatal populations of
neurons.126
Other neurodegenerative diseases where CK2 is a major player are: Huntington´s disease, amyotrophic
lateral sclerosis and Alzheimer´s disease. There are several CK2 substrates that have been studied in vivo
that play a role in neurodegenerative diseases and modification of CK2 might prove a novel target in the
treatment of neurological and neuropsychiatric disorders127.
Kinases are a relatively unexplored protein family in depression research, yet they have the advantage of
being readily targeted with high specificity with small molecules. GSK3, for example, is a ubiquitously
expressed kinase and a pharmacological target in treating affective disorders since it mediates the action
of lithium in the treatment of bipolar disorder128. Pharmacological inhibition of GSK3 produced an
antidepressant response in rodents129 and enhanced the antidepressant effect of sub-threshold doses of
ketamine130,131.
So far, the only information about expression of CK2 in the brain is derived from mRNA studies (Allen Brain
Atlas) and western blot quantifications across some brain regions 132.
In Chapter 3 we present a small project where we mapped the expression of the three different CK2
subunits, CK2α, CK2α’ and CK2β in the mouse brain using immunofluorescence. This will provide
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molecular detail about the expression of each subunit and their specific localization and allow the
comparison between transcriptional and protein expression.
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Chapter 3
CK2 expression in the mouse brain
Adapted from 2017 publication: Julia Castello, Andre Ragnauth, Eitan Friedman and Heike Rebholz.
“CK2- an emerging target for Neurological and Psychiatric Disorders” Pharmaceuticals (2017) 10(1), 7

3.1. Introduction
Expression of CK2 is ubiquitous through the periphery as well as in the brain but there are interesting
patterns, both at the transcriptional (as shown in the Allen Brain Atlas) and protein levels in the stoichiometry
between CK2α, CK2α’ and CK2β133,134. Quantification of mRNA expression and protein level of each CK2
subunit across different brain regions are depicted in Figure 3.1 and 3.2; from Ceglia et al (2011). At the
mRNA level, CK2α expression is the most consistent throughout brain regions while expression of
CK2α´and CK2β is more heterogeneous (Figure 3.1). Overall, there seems to be an imbalance of the CK2β
subunit when compared to CK2α and CK2α´ combined, since it resembles more closely the levels of CK2α,
indicating that the regulatory CK2β subunit might not always be essential to the functionality of CK2α and/or
CK2α´.
At the protein level, CK2α predominates over CK2α´ throughout the brain. Examples are the mouse
striatum, where the ratio CK2α: CK2α´is 8:1 and the hippocampus, where the ratio is 4:1 as indicated by
Western Blot measurements134 (Figure 3.2).
For this first project involving CK2, we found necessary to add information about the expression of the three
CK2 subunits at the protein level. We performed immunohistochemical analysis of saggital brain slices to
provide a more detailed overview of the distribution of each subunit in the mouse brain since the western
blotting technique is limited by the inaccuracy of manual dissections.

18

Figure 3.1. CK2 isoform mRNA expression levels in seven major brain regions. In situ hybridizations for
CK2α (a) CK2α´(c) and CK2β (e) on sagittal adult mouse brain. Quantification of expression levels for CK2α (b)
CK2α´(d) and CK2β (f). CB Cerebellum, Ctx Cortex, HC hippocampus, hypo hypothalamus, Olf olfactory bulb, Str
striatum, Tha thalamus. From Ceglia et al. Predominance of CK2α over CK2α´in the mammalian brain. Mol.
Cell Biochem (2011)
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Figure 3.2. CK2 isoform protein levels in the nine major brain regions. Western blot documenting CK2α,
CK2α´and tubulin protein expression (a) and quantification across brain regions of CK2α (b) and CK2α’ (c).
From Ceglia et al. Predominance of CK2α over CK2α´in the mammalian brain. Mol. Cell Biochem (2011)
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3.2. Materials and Methods
Immunohistochemistry
Animals were anesthetized with pentobarbitol and transcardially perfused with 10ml PBS followed by 50
ml of 4% paraformaldehyde (PFA) in PBS. PFA-perfused brains were sliced sagittally (40μm). Free-floating
slices were washed in 3xPBS for 10min, permeabilized with PBS-T 0.05% for 10 min, blocked for 1hour
with 10% Horse Serum and incubated in α-CK2α, α-CK2α´(Abcam), α-CK2β (gift from Dr. O. Filhol,
Grenoble) and α-NeuN (Cell Signaling) overnight. Free-floating sections were incubated for 2 hours at RT
with Alexa Fluor 546 or Alexa Fluor 488 (Thermo Firscher Scientific) and mounted using Prolog gold with
dapi antifade reagent (Invitrogen) Imaging was performed with a Zeiss LSM710 laser-scanning confocal
microscope.

3.3.

Results

Overall, mRNA levels coincided with protein levels of the different subunits across brain regions (Figure
3.3A). However, some interesting patterns could be detected. In the hippocampus, CK2α and CK2α´ were
present and protein expression corresponded to mRNA quantification. In the case of CK2β, mRNA
expression was the highest in the hippocampus when compared to other brain regions, but at the protein
level, CK2β appeared to be absent from the soma of neurons in the dentate gyrus of the hippocampal
formation as well as from CA1, CA2 and CA3 regions (Figure 3.3A, CA2 in higher magnification in Figure
3.3B). Nevertheless, CK2β and CK2α coexisted in most other areas and the prefrontal cortex is shown as
representative example (Figure 3.3B´).
The pontine grey nucleus is a region responsible for motor function regulation (Figure 3.3A) and presented
high expression of the three CK2 subunits. Nevertheless, as indicated by NeuN staining (a marker present
in all mature neurons except Purkinje cells, olfactory mitral cells, Cajal-Retzius cells and neurons of the
inferior olive) the pontine grey has high cell density causing an elevated immunosignal rather than increased
CK2 concentration.
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Interestingly, CK2α was highly expressed in the olfactory bulb and the ratio CK2α: CK2α´ is 24:1. We were
able to confirm these results by immunohistochemistry. While we clearly observed co-localization between
CK2α and CK2β we were unable to detect any CK2α´ despite significant mRNA levels in that region (Figure
3.3C). We identified the cells expressing CK2β as olfactory mitral cells since NeuN was not detected
(olfactory mitral cells are one of the few cell types that are not stained with NeuN). (Figure 3.3C).
In the cerebellum, CK2α and CK2β are homogeneously present in large GABAergic Purkinje cells, while
CK2α´ expression was scattered. All isoforms were sporadically present in the molecular and granular
layers of the cerebellar folium (Figure 3.3D).

22

23

Figure 3.3. Immunohistochemical analysis of sagittal brain slices of adult C5BL/6 mice. Slices were
stained for CK2α, CK2α’ and CK2β (A). The hippocampal CA1 region and PFC were stained with CK2α
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and CK2β (B). Olfactory bulb was stained for CK2β and NeuN and for CK2α’ (C). Cerebellum was stained
for CK2α, CK2α’ and CK2β and NeuN (D) PG = Pontine grey nucleus; white bars=100µm

3.2.

Discussion

Our observations at the molecular level of the expression of the three different CK2 subunits confirmed a
ubiquitous expression mostly in all the cells with few exceptions like the hippocampus, olfactory bulb and
cerebellum.
In agreement with previous literature, we did not find a brain region where CK2α’ expression dominates
over CK2α. This observation does not imply that CK2α´does not have a specialized vital function in the
brain such as substrate-specific binding or localization to specific microdomains or subcellular structures.
In fact, the clustered pattern seen in the Purkinje cells of the cerebellum may be of physiological relevance.
It will be interesting to take a closer look at the expression profile on a cellular level, including the use of
glial markers and assess the differences in subunit expression in different cell types across brain regions.
Interestingly, we were not able to detect CK2β in the hippocampus where CK2α is homogeneously
distributed. It is known that the catalytic subunit CK2α can be active independently from the regulatory
subunit CK2β with a modified enzymatic activity135-137 but the study of the hippocampus could hold an
additional clue for understanding CK2β – independent CK2α substrates and regulatory mechanisms.
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Chapter 4
Behavioral phenotype of the CK2 KO mice
Adapted from 2018 publication: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like
behavior” Molecular Psychiatry (2018) 23, 872-882

4.1 Introduction

The role of CK2 in neurodegenerative disorders has been barely studied. Previous work established CK2
as a regulator of dopaminergic signaling and its possible implication in the formation of LID in Parkinson’s
disease. In vitro, inhibition of CK2 increased dopamine 1 receptor (D1R) levels at the plasma membrane
as well as adenosine 2 receptors (A2a) establishing CK2 as regulator of Gαs signaling125,138.
Pharmacological studies of CK2 in vivo are challenging because available CK2 inhibitors like DMAT or TBB
do not cross the blood-brain barrier (BBB)127. A promising candidate, CX4945 permeates the BBB and has
been proven to be safe when administered orally in glioblastoma-bearing mice121. CX4945 is currently
undergoing clinical phase II in humans as a potential treatment for cancer (ClinicalTrials.gov Identifier:
NCT02128282). However, given the ubiquitous expression of CK2, intraperitonial administration at doses
required for behavioral assessment in mice leads to peripheral and central side effects such as rigidity that
need to be further characterized. To study the effects of inhibiting CK2 in the brain, KO mice can be of great
use. Full CK2α KO mice are embryonically lethal and only survive until embryonic day E11.5 with defective
neural tube and heart139. CK2β KO mice are reabsorbed on E7.5140. Full CK2α´mice are viable but males
are sterile141. Therefore, we generated conditional CK2 KO mice where the α catalytic subunit was ablated
in cells expressing the D1 receptor (Drd1a-Cre-CK2α) or in cells expressing the D2 receptor (Drd2-CreCK2α) for behavioral and molecular characterization.

Rebholz et al. previously showed that the Drd1a-Cre-CK2α KO mice, unlike the Drd2-Cre-CK2α KO mice
presented altered dopaminergic signaling. In a mouse model of PD, the behavioral response to L-DOPA126,
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the main treatment to counteract akinetic symptoms in PD, was altered in CK2 conditional KO mice. When
the Drd1a-Cre-CK2α KO mice were placed in an open field arena, presented a hyperlocomotive phenotype
that was normalized to WT levels after D1R antagonist administration. Interestingly, they also spent more
time in the center of the open field when compared to WT animals. In the novelty suppressed feeding
(NSF) test, animals were starved for 24 hours, then placed in an open field environment with a food pellet
in the middle of the arena. When latency to eat was quantified, the Drd1a-Cre-CK2α KO mice presented a
reduced latency to bite the food pellet for the first time when compared to WT littermates, while the total
food intake was not altered124. These two behaviors were indicative that the Drd1a-Cre-CK2α KO mice
presented an anxiolytic-like phenotype. Rebholz et al further investigated the phenotype using Porsolt tests
of behavioral despair such as the forced swim test (FST) and the tail suspension test (TST). The Drd1aCre-CK2α animals were less immobile during the 4 min task than WT animals. Nevertheless, both FST and
TST are locomotion-dependent tasks. In order to normalize locomotion levels between groups, mice were
administered D1R antagonist, SCH (0.03 mg/kg), 10 min before testing. Although to a lesser extent, a
reduced time immobile in the FST and TST was still significant when comparing the Drd1a-Cre-CK2α KO
animals to their WT littermates138.

Driven by this intriguing phenotype, we decided to further characterize the anxiolytic/ antidepressant- like
phenotype of the Drd1a-Cre-CK2α KO mice.

4.2 Materials and Methods

Reagents
Monoclonal antibody α-CK2α was purchased from Cell Signaling Technology (Danvers, MA), α-CK2α’ and
α-CK2β from Abcam (Cambridge, MA) AND α-tubulin from Sigma (St. Louis, MO). Fluoxetine and
Imipramine were purchased from Sigma-Aldrich (St. Louis, MO)
Animals
The generation of the floxed CK2α line was decribed in138 animals were bred on a C57/BI6 background.
The Drd1a-Cre line was derived from EY262 founder line (Gensat) and the Emx1-Cre line from Jackson
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Laboratories (Jackson 005628, Bar Harbor, ME, USA). Animals (4-7 months old) were used and mice were
maintained in a 12 h light/dark cycle, with access to food and water ad libitum. Animal procedures were in
accordance with NIH guidelines and approved by CCNY’s IACUC.
Elevated plus maze
The mice were placed in the middle of the elevated plus maze (50 cm from the floor) and allowed to explore
the maze for 6 min. Time spent in open and closed arms and in the center square were scored and time
spent in open and closed arms was plotted.
Light-dark test
The mice are placed in a cage divided in two equal size sections interconnected by a door. One chamber
is opened and illuminated while the other chamber is closed and dark. The door avoids light to enter the
dark chamber. Mice are allowed to move freely for 10 min and time spent in each chamber is quantified.
Sucrose preference test
The sucrose preference test was conducted using a two-bottle choice procedure using single housed mice.
For 24 h mice were habituated to 1% (w/v) sucrose for 24 h. On day −1, mice were denied access to fluid
but had free access to food for 16 hours. On the test day, mice were given access to the two pre-weighed
bottles, one containing tap water and one containing 2% (w/v) sucrose, were left undisturbed for 1 hour
before fluid consumption was measured. The test was repeated starting with re-habituation, deprivation
and testing, and results from both tests were combined. The position of sucrose bottles were randomly
assigned and changed. The preference for sucrose over water (sucrose/water) was used as the measure
of the preference for sucrose.
Nesting behavior
Animals were single housed overnight and a square cotton pad was added to the cage. After a 16-hr period,
scores were attributed according to the following criteria: 0: Nestlet (square cotton pat) not noticeably
touched (more than 90% intact). 1: Nestlet partially torn (50-90% remaining intact). 2: Nestlet mostly
shredded but 30-50% of chunk piece remaining not torn and the shredded cotton not gathered entirely. 3:
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Nestlet mostly shredded and gather into one flat pat. 4: Nestlet torn, > 90%, and nest built looks like a
crater, with wall surrounding higher than mouse body height, >50%.
Open field
Locomotion was measured using the open field analysis in a new environment (clear Plexiglas 40 x 40 x
30 cm open-field arena). Mice were recorded with a digital camera for the total distance moved (cm). Data
were collected for 10 min intervals. Recordings were analyzed with Ethovision software (Noldus).
Tail suspension test
Mice were individually suspended by the tail from a horizontal bar (distance from floor was 35 cm) using
adhesive tape (distance from tip of tail was 2 cm). A 6 min test session was videotaped and time spent
immobile during the last 4 min was scored by a blind observer.
Forced swim test
Briefly, mice were placed in a glass cylinder (16 cm diameter, 25 cm height) filled with water (23-25°C) to
a height of 20 cm. Immobility, defined as the absence of all motions except those required to keep the
mouse's head above water, was determined for the last 4 min of the 6 min test. When animals were tested
in more than one paradigm, the experiments were spaced at least 4 days apart.
Novelty suppressed feeding
The mice were single caged and depleted from food 24 hours before the test. Mice were placed individually
in the corner of an open field arena filled with bedding and containing one pellet of food on a squared
4cmx4cm paper. Latency of each mouse to grab the food pellet and take the first bite was quantified
Sample preparation and Western Blot analysis
All animals were sacrificed by decapitation. Animal brains were rapidily dissected. Tissues were snapfrozen in liquid nitrogen. Tissues were lysed in 2% SDS, sonicated for 3x10 sec, boiled and cleared by
centrifugation for 20 min at 13000 rpm. Protein concentration was determined with a BCA kit (Pierce). 30
µg of protein per well were used for SDS-PAGE, proteins were transferred onto nitrocellulose, incubated
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with CK2α, CK2α’, CK2β or α-tubulin antibodies overnight and detected by enhanced chemiluminescence
(FluorChemE, Protein Simple). Quantification was performed using Image J software
Immunohistochemistry
Animals were anesthetized with pentobarbitol and transcardially perfused with a 10 ml PBS wash followed
by 50 ml of 4% PFA in PBS. PFA perfused brains were sliced coronally (30μm). Free-floating slices were
washed in 3xPBS for 10min, permeabilized with PBS-T 0.05% for 10 min, blocked for 1hour with 10% Horse
Serum and incubated in α-CK2α (Abcam) overnight. Free-floating sections were incubated for 2 hours at
RT with Alexa Fluor 546 (Thermo Firscher Scientific) and mounted using Prolog gold with dapi antifade
reagent (Invitrogen) Imaging was performed with a Zeiss LSM710 laser-scanning confocal microscope.
RNA extraction and real time PCR
Brain tissue from the PFC, hippocampus and striatum was homogenized and extracted using TRIZOL (Life
Technologies). 5 to 10µg of total RNA was treated with TURBO DNAse (Ambion) and cDNA was
synthesized using 1-2 µg of DNA-free RNA and the High-capacity cDNA reverse transcription kit with
random primers (Applied Biosystems). Relative mRNA levels were quantified on a Realplex PCR machine
(Eppendorf)
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4.3. Results

4.3.1 Mood related behaviors are affected by CK2

Animals lacking the catalytic subunit of CK2 in D1-MSN (Drd1a-Cre-CK2α), presented reduced CK2α levels
in the striatum and the cortex. Rebholz et al. previously showed that Drd1a-Cre-CK2α mice when compared
to WT littermates: spent less time immobile in the FST and the TST, showed reduced latency to eat in the
NSF test and spent more time in the center of an open field arena138. To further confirm that CK2 affects
anxiety-like behaviors, we tested mice in the elevated plus maze (EPM) and the light-dark test (LDT).

The EPM consist of a maze with two enclosed arms and two open arms that is 50 cm elevated from the
floor. The open arms induce an avoidance conflict while the closed arms do not142. While WT animals
showed an inclination for the closed arm over the open arm, Drd1a-Cre-CK2α KO animals did not show a
preference, indicative of an anxiolytic-like behavior (Figure 4.1A). The light-dark test measures anxiety in a
non-coditionated environment – without a particular stressor143. Mice could spend time in a bright and open
compartment or in a covered dark compartment. The Drd1a-Cre-CK2α KO mice spent significantly less
time in the dark compartment when compared to WT littermates (Figure 4.1B). We used the sucrose
preference (SP) test to assess anhedonia; a common condition in depressive-like states characterized by
the inability of experiencing pleasure. In the SP test, mice are given the choice between drinking plain water
or a 1% sucrose solution. The Drd1a-Cre-CK2α KO mice, significantly consumed more sucrose solution to
water than WT animals (Figure 4.1C) without differences in drinking behavior or food consumption (Figure
4.1D and 4.1E). Finally, the Drd1a-Cre-CK2α KO animals showed a reduction in nesting behavior (Figure
4.1F). Nesting was assessed by providing a cotton pad to single caged animals over a period of 16 hours.
While WT animals formed a volcano-shaped nest, Drd1a-Cre-CK2α KO mice left the pad almost intact.
Whether nesting is a measure of depression-like symptoms has been controversial, but it was shown that
animals treated with antidepressants reduced their nesting behavior in a dose dependent manner 144.
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Figure 4.1. Knockout of CK2α in cortex and striatum causes anti-depressant-like phenotype in
Drd1a-Cre-CK2α KO mice. Male Drd1a-Cre-CK2α KO spent more time in the open arms of the elevated
plus maze (N=13 WT, N=11 KO) (A) and less time in the dark compartment of the light-dark test (N=9
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WT, N=11 KO) (B) Sucrose/water consumption was elevated in the male Drd1a-Cre-CK2α KO (N=14
WT, N=13KO) (C) without changes in liquid intake (D) or food consumption (E). Nesting behavior was
decreased in Drd1a-Cre-CK2α KO mice (N=8 WT N= KO)(F).Graphs show the mean values ±S.E.M.
Statistical analysis was performed using two-way ANOVA with Tukey’s post-test. F(1,52) = 12.17, p=0.001
(A) and unpaired two-tailed Student’s test (B-F), (*P<0.05,**P<0.01, ***P<0.001)

The Drd1a-Cre-CK2α KO animals presented a hyperlocomotive phenotype (Figure 4.2A and 4.2B) most
likely due to the upregulation of the D1R in the striatum caused by the absence of CK2α125. Unfortunately,
the nature of many of the behavioral tests used to assess depressive- and anxious- like states are
dependent on the locomotion of subjects. For this reason, we generated Emx1-Cre-CK2α KO mice
(CK2αfl/fl, Emx1-Cre(+/-)) that lack expression of CK2α in the cortex and the hippocampus and were not
hyperlocomotive compared to WT littermates (Figure 4.2) We characterized the reduced expression of
CK2α in vivo in the Emx1-Cre-CK2α line by immunohistochemistry and western blot analysis (Figure 4.3)
and found no alterations of protein expression of CK2α’ or CK2β subunits.
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Figure 4.2. Emx1-Cre-CK2α KO mice are not hyperlocomotive. Locomotion in male Drd1a-Cre-CK2α
(A) B) and of the Emx1-Cre-CK2α mice (C,D) and WT littermates was measured as total distance travelled
in an open field environment for 10 minutes (N= 7-8 for Drd1a-Cre-CK2α KO cohort, N=14-15 for Emx1Cre-CK2α KO). Plotted are mean values (± SEM). Statistical analysis was performed using two-way
ANOVA F(1,120) = 50.75, p<0.0001 with Bonferroni’s post-tests (*, p<0.05; **, p<0.01; ***, p<0.001) (A,C)
and unpaired two-tailed Student’s test (**, p<0.01) (B,D)
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Figure 4.3. CK2α expression is reduced in the Emx1-Cre-CK2α KO mice. Western blotting analysis of
male Emx1-Cre-CK2α KO or WT littermates tissues using anti-CK2α, anti- CK2α’, anti-CK2β and tubulin
antibodies (A). The bottom band in the panel showing CK2α’ is the band that appears upon re-probing the
membrane derived from the CK2α-blot with anti-CK2α’ antibody. Immunohistochemical analysis of CK2α
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expression in PFC, hippocampus and striatum using coronal slices derived from Emx1-Cre-CK2α KO or
WT littermates using anti-CK2α antibodies (B)

Next, we tested Emx1-Cre-CK2α mice in paradigms of anxiety and depression: both in the TST and the
FST, Emx1-Cre-CK2α KO animals spent less time immobile than their WT littermates (Figure 4.4A and
4.4B). In the EPM, WT animals spent significantly more time in the closed arm while Emx1-Cre-CK2α KO
did not show a preference (Figure 4.4C). Furthermore, there was a significant difference in the time spent
in the open arm between WT and Emx1-Cre-CK2α KO, being Emx1-Cre-CK2α KO higher. In the SP, Emx1Cre-CK2α KO preferred intake of 1% sucrose solution over water by a factor of 1.9 over WT (Figure 4.4D).
In the NSF, the latency to eat in the Emx1-Cre-CK2α KO mice was significantly reduced compared to WT
littermates (Figure 4.4E) without differences in their feeding behavior (Figure 4.4F).

All the above discussed results were derived from male cohorts but we were able to reproduce the
phenotype in female cohorts with similar results in all tests in the Emx1-Cre-CK2α and in all tests except
for the NSF and SP in the Drd1a-Cre-CK2α line. (Figure 4.5)
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Figure 4.4. Knockout of CK2 in cortex and hippocampus causes antidepressant-like behavior in
Emx1-Cre-CK2α mice. Male Emx1-Cre-CK2α KO mice presented reduced immobility in (A) tail
suspension test and (B) forced swim test (N=9 WT, N=11 KO for A and B), they spent more time in the
open arm of the (C) elevated plus maze (N=7 WT, N=9 KO), consumed more sucrose to water in sucrose
preference test (D) and presented reduced latency to eat in novelty supressed feeding test (E) without
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changes in food consumption (F) (N=8 WT, N=7 KO for D,E and F). Tests performed with a cohort of
male Emx1-Cre-CK2α KO mice and WT littermates. Graphs show mean values ±S.E.M. Statistical
analysis was performed using two-way ANOVA with Tukey’s post-test: F(1,28)=12.03, P=0.002 (C) and
unpaired two-tailed Student’s test (A,B,D-F), (*P<0.05,**P<0.01, ***P<0.001)
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Figure 4.5 . Knockout of CK2 causes anti-depressant-like behavior in female mice. Female Drd1aCre-CK2α KO mice compared to WT littermates did not have a preference for either arm of the elevated
plus maze (A) showed reduced immobility times in tail suspension test (B) aswell as forced swim test (C).
Female Emx1-Cre-CK2α KO mice compared to WT littermates showed a preference for the open arm in
the elevated plus maze (D) decreased immobility time in the tail suspension test (E) and in the forced
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swim test (F), presented reduced latency to eat in the novelty supressed feeding test (G) and increased
sucrose/water consumption in the sucrose preference test (H). For the Drd1a-Cre mice (N=7 WT, N=7
KO). For the Emx1-Cre ( N=7 WT, N=5 KO). Graphs show the mean values ±S.E.M. Statistical analysis
was performed using two-way ANOVA with Bonferroni’s post test: F(1,24)=10.64, P=0.0033 (A);
F(1,20)=21.55, P=0.002 (D), and unpaired two-tailed Student’s t-test (B,C,E-H) (*P<0.05,**P<0.01,
***P<0.001)
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Figure 4.6. Drd1a-Cre-CK2α KO mice are more susceptible to antidepressant treatment than WT
littermates. Mice were given an acute injection of either imipramine (N=7 WT, N=6 KO) or fluoxetine (N=11
WT, N=10 KO) 30 min before tail suspension test (A,B). Mice were injected once daily for 15 days with
10mg kg-1 fluoxetine. The last injection was administered 30 min before tail suspension tests (N=10 WT,
N=9 KO) (C). Graphs show the mean values ±S.E.M. Statistical analysis was performed using one-way
ANOVA F(1,24)=10.64, P=0.0033 (A); F(1,20)=21.55, P=0.002 (D), and unpaired two-tailed Student’s t-test
(B,C,E-H) (*P<0.05,**P<0.01, ***P<0.001)
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Once confirmed the antidepressant phenotype in both KO lines, we were intrigued to test the
responsiveness of the Drd1a-Cre-CK2α KO mice to antidepressant drugs using a tricyclic and an SSRI,
imipramine and fluoxetine, respectively. In the TST, Drd1a-Cre-CK2α KO mice displayed a significant
reduction of immobility time to a 5mg/kg imipramine dose while WT did not respond (Figure 4.6A). For
fluoxetine, a dose of 20mg/kg was required for Drd1a-Cre-CK2α KO animals to respond while at this
same dose, WT animals did not show any effect (Figure 4.6B). When fluoxetine was chronically
administered for 2 weeks, both groups were responsive to treatment and showed a reduction of the
immobility time in the TST although this reduction was more dramatic for the Drd1a-Cre-CK2α KO (factor
of 7.8) than for WT (factor of 1.7) (Figure 4.6C).
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4.3.2. 5-HT4R expression is elevated in CK2α KO mice
Given the antidepressant- and anxiolytic- like behavior of Drd1a-Cre-CK2α KO and in Emx1-Cre-CK2α KO
mice when compared to their corresponding WT littermates as well as the increased susceptibility to
antidepressant drugs of the Drd1a-Cre-CK2α KO mice, we hypothesized that there must be some alteration
in the serotonergic system. Since we previously showed that CK2 modulates Gαs signaling125, we primarily
evaluated Gαs-coupled serotonin receptors (5-HT4, 5-HT6) as well as those 5-HT receptors that have been
described as key players in regulating serotonergic tone (5-HT1A and 5-HT1B autoreceptors) and that were
most relevant due to their expression profiles: we were interested in studying receptors expressed in the
regions where CK2α was ablated in Drd1a-Cre-CK2α (striatum, cortex) and Emx1-Cre-CK2α
(hippocampus, cortex). The 5-HT1B receptor is highly expressed in striatum and cerebellum 145-148. 5-HT4
and 5-HT6 in cortex, striatum and hippocampus55,149. We also quantified the expression profile of p11 since
it has been found to regulate HTR4 expression and mice lacking p11 did not respond to antidepressant
treatment150. Since the only region of overlap of Cre expression of the two mouse lines (Drd1a-Cre-CK2α
and Emx1-Cre-CK2α) was the cortex, we focused on the prefrontal cortex (PFC) which has been described
as a major brain substrate involved in MDD151-153. We assessed mRNA expression levels of the serotonin
receptors by quantitative RT-PCR. We found that in the Drd1a-Cre-CK2α KO there was a 26% upregulation
of the HTR4 while there was not a significant change in other receptors or protein p11 (Figure 4.7A). When
quantifying HTR4 expression in the striatum, where CK2α was also ablated, we observed no difference
(Figure 4.7B). In the Emx1-Cre-CK2α KO we found a 30% upregulation of HTR4 without alteration in mRNA
levels of other receptors or protein p11 (Figure 4.7C). We then analyzed the expression profile of the HTR4
in the dorsal and ventral hippocampus (Figure 4.7D and Figure 4.7E). While the dorsal hippocampus is
involved in cognition, the ventral hippocampus plays an important role in the modulation of emotion, affect
and stress responses154. We did not observe any significant change between subregions of the
hippocampus.
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Figure 4.7. HTR4 expression is altered in the absence of CK2. Quantitative RT-PCR performed on PFC
tissue (A) or PFC and striatal tissue (B) from Drd1a-Cre-CK2α KO and WT littermates (N=13 WT, N=14
KO) for PCF and (N=6 WT, N=8 KO) for striatum; quantitative RT-PCR performed on PFC tissue (C) or
PFC and hippocampal tissue (D) or dorsal and ventral hippocampal tissue (N=7 WT, N=7 KO) (E) from
Emx1-Cre CK2α KO mice and WT (males) (N=7 WT, N=6 KO). Graphs show the mean values ±S.E.M.
Statistical analysis was performed using unpaired two-tailed Studen’s test comparing different PCR probes
between genotypes (A-E) (*P<0.05,**P<0.01)
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4.4 Discussion

Our experiments establish a novel link between CK2α and the 5-HT4R at the transcriptional level. The first
line of conditional CK2α KO mice, the Drd1a-Cre-CK2α, presented a behavioral phenotype reminiscent of
antidepressant treated animals in FST, TST, EPM, NSF, SP as well as altered nesting behavior. We
generated a second KO line, Emx1-Cre-CK2α, and mice phenocopied the Drd1a-Cre-CK2α. This line had
the advantage that locomotor activity was not changed in CK2α KO mice, confirming the importance of
CK2α as a modulator of depression- and anxiety-like phenotypes in mice. Importantly, while the TST and
the FST are sensitive to acute antidepressant treatment155,156, the NSF test also showed a significant
difference between genotypes in both mouse lines. This is particularly relevant considering that this test is
only sensitive to chronic antidepressant treatment157, suggesting that the molecular changes caused by
CK2 produced an effect that was comparable to chronic administration of antidepressant drugs.

Given the phenotype of the CK2 KO mice, we hypothesized that there might be alterations in the
serotonergic system. Thus, we tested the responsiveness of Drd1a-Cre-CK2α to antidepressant drugs and
found that, when administered accutely, KO animals responded to lower doses of imipramine as well as
fluoxetine. In addition, when fluoxetine was administered for 15 days, both groups responded in the TST
but KO mice reduced the time immobile to a larger extent. These results indicate that absence of CK2
increases susceptibility to antidepressant drug treatment.

Analyzing the mRNA expression profiles of different serotonin receptors we identified a Gαs-coupled
receptor, the 5-HT4R but not other serotonin receptors or protein p11( a protein necessary to mediate the
behavioral response of 5-HT4R agonist and antidepressant treatment in mice76) to be upregulated in the
PFC of both Drd1a-Cre-CK2α and Emx1-Cre-CK2α KO mice. This upregulation was specific to the PFC
since other brain regions where CK2α was also ablated such as striatum in the Drd1a-Cre-CK2α and
hippocampus in the Emx1-Cre-CK2α did not show significant changes in the 5-HT4R mRNA levels.
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Taken together, we found that in two different mouse lines, the absence of CK2α alters the serotonergic
system in a very specific manner, resulting in an antidepressant- and anxiolytic- like phenotype as well as
in an increased susceptibility to antidepressant treatment. Molecularly, ablating CK2α upregulates HTR4 in
the PFC. Therefore, we next aim to confirm if knockdown of CK2α in adult mice, through upregulation of
the 5-HT4R is responsible for the antidepressant/anxiolytic-like phenotype observed in the CK2α KO mice
and if the PFC alone is the brain region responsible of mediating the phenotype.
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Chapter 5
CK2 regulates 5-HT4 receptor expression/signaling in vitro and in vivo
Adapted from 2018 publications: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like
behavior” Molecular Psychiatry (2018) 23, 872-882

5.1. Introduction
GPCRs are the largest protein family in the human genome and consist of over 800 members 158. GPCRs
are responsible for mediating the biological actions of neurotransmitters, hormones, pheromones, light, and
calcium through the activation of one or more of the four G protein families: Gα i/o, Gαq/11 Gαs and Gα12/13.
GPCR cell surface expression and coupling to G proteins are regulated by phosphorylation of their third
intracellular loop and/or their C-terminal region by different Ser-Thr kinases159. CK2 has been described as
capable of phosphorylating GPCRs such as M3 muscarinic receptor 160. A different involvement of CK2 in
the regulation of GPCRs in the brain was identified by Rebholz et al. following a yeast-two-hybrid screen
assay which yielded the G protein subunit Gαs as a CK2β interacting partner in cultured cells and in brain
tissue. The complex also contained CK2α, indicating that the CK2 holoenzyme is bound to Gα s. Only Gαs
and no other Gα subunit precipitated with CK2β. In addition, inhibition of CK2 or siRNA targeting CK2α
reduced agonist-induced receptor endocytosis in cultured cells and concomitantly enhanced receptor
signaling, suggesting a negative regulation of Gαs by CK2. This regulatory effect was also observed tor the
Gαs –coupled adenosine A2a receptor. Activation of the Gαs subunit leads to stimulation of adenylate
cyclase which yields to accumulation of cAMP.
MDD is linked to dysregulation of the serotonergic system in the brain. Out of the fourteen different types
of serotonin receptors, three are coupled to Gαs.
In chapter 4, we described how in vivo, one of the serotonin receptor subtypes, the 5-HT4R, was
upregulated in the PFC in the absence of CK2α at the transcriptional level. In this chapter, we aim to further
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characterize how CK2 regulates 5-HT4R. For this purpose, we performed in vitro luciferase assays to
understand possible transcriptional modifications of the activity of the HTR4 promoter. We also aim to
identify if there is a post-translational regulatory mechanism involved. We assessed in vitro alterations in
the expression of 5-HT4R at the plasma membrane as well as activation of the 5-HT4R through production
of

cAMP

after

pharmacological

inhibition

or

knockdown

of

CK2.

We

confirmed

elevated

expression/signaling in vivo at the protein level by assessing activation of pERK, a downstream effector in
the

non-canonical

5-HT4R

signaling

cascade

in

the

mPFC

of

mice.

Unfortunately,

direct

immunohistochemical staining of 5-HT4R was not possible due to the lack of effective antibodies.
5.2 Materials and methods
Reagents
Monoclonal antibody α-pThr202/Tyr204 ERK was purchased from Cell Signaling Technology (Danvers,
MA). CX4945 was a present from Dr. S O’Brien (Cylene Pharmaceuticals). DMAT, TBB were purchased
from Calbiochem. Sufo-NHS-LC-Biotin and streptavidin beads were from Pierce. RS67333 and GR113808
was from Tocris (Ellisville,MO). HA-HTR4(a) in pRK5 was a gift from Dr. S. Claeysen, CNRS Montpellier,
France,
Cell lines
COS7 and HeLa cells were kept in DMEM supplemented with 10% dialyzed FBS and non-essential amino
acids at 37ºC in 95% air/5% CO2 atmosphere. Knockdown of CKα was achieved by infecting cells with a
lentivirus expressing a CK2α-specific shRNA (pGIPZ shCK2) or non-targeting shRNA as a control (GE
Healthcare). Briefly, cells were infected at an MOI of 10, and 72 h post-transfection, cells stably transduced
with CK2αsh or Ctrlsh were selected for at least 7 days in presence of 2µg /mL (HeLa) and 3µg/mL (COS7)
puromycin (Sigma). For signaling experiments, COS-7 cells were transiently transfected with HA-HTR4(a)
or control plasmid using polyethylenimine (PEI) and treated as indicated 48 h after transfection.

Luciferase assays
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A 4139 bp gDNA fragment corresponding to the region directly upstream of the mouse HTR4 mRNA first
exon (NM_ 008313.4), was amplified by PCR using N2A gDNA as template, Accuprime Pfx DNA
polymerase (Life Technologies) and HTR4 promoter sense (5’-GGGAAGAGAGG AGAGCCTTGC-3’) and
antisense primers ( 5’-CCTTTAGCGCAGAACCCTGC-3’) containing XmaI and BglII restriction sites,
respectively. The resulting PCR product was digested and cloned in the XmaI/BglII sites of the pGL3B
reporter construct (Promega). 1x105 wild-type HeLa cells were co-transfected with 750 ng each of the
reporter construct and pCMV β-galactosidase using Lipofectamine 2000 (Life Technologies). Treatment
with CX4945 (or DMSO) was started after 24 hours. 48h post-transfection cells were lysed in reporter lysis
buffer. Extracts were frozen at -20˚C, thawed and cleared by centrifugation at 15,000 rpm. Luciferase and
β-galactosidase activities were measured using luciferase assay reagent (Promega) and chlorophenol redβ-D-galactopyranoside (CPRG, SantaCruz Biotechnologies). Relative luciferase activity was normalized to
β-galactosidase activity to correct for transient transfection efficiency.
cAMP assay
COS-7 cells were treated as indicated and lysed in HCl. The concentration of cAMP from lysates was
determined according to the manufacturer’s instructions (Enzo).
Surface biotinylation
Transfected COS-7 cells were washed twice with ice-cold phosphate-buffered saline containing 1 mM
CaCl2 and 1 mM MgCl2 and then incubated twice at 4°C with 0.5 mg/ml NHS-LC-biotin (Pierce) for 20 min
each time to biotinylate cell surface proteins (1). Cell lysate was prepared in immunoprecipitation buffer (20
mM Tris.HCl 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100, 0.1% SDS) with protease inhibitor mixture
(Roche). Streptavidin-agarose beads (Pierce) were used to affinity purify biotinylated proteins. Quantitative
western blots were performed on total and biotinylated (surface) proteins using NIH Image 1.63 software.
The surface/total ratio of overexpressed HA-HT4R was calculated for each sample.

Sample preparation and Western blot analysis
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Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 mM EGTA,
1% Triton Xphosphatase inhibitors, and cleared by centrifugation. Protein concentration was determined with a BCA kit
(Pierce). 30 μg of protein per well were used for SDS-PAGE, proteins were transferred onto nitrocellulose,
incubated with antibodies overnight and detected by enhanced chemiluminescence (FluorChemE,
ProteinSimple). Quantification was performed using ImageJ software
Immunohistochemistry
Male mice were injected for 7 days with saline solution. On pefusion day, mice were administered saline
solution or GR113808 (0.1 mg/kg, i.p.), 30 min before sacrifice. Animals were anesthetized with
pentobarbitol and transcardially perfused with a 10 ml PBS wash followed by 50 ml of 4% PFA without PBS
wash. Brains were incubated overnight in 30% sucrose and sliced at a thickness of 30 μM. pERK
(T202/Y204) was visualized using indirect immunofluorescence analysis (Alexa-Fluor 546 anti-rabbit IgGs
(H+L) dilution 1:500, Invitrogen). Sections were mounted using Prolong Gold (DAPI) antifade (Invitrogen).
Confocal microscopy was performed using a Zeiss LMS 710 laser-scanning confocal microscope using the
same adjustments for all the sections. Counting was performed manually in 375 x375 μm confocal images
in blind conditions concerning

50

5.3 Results
5.3.1. CK2α regulates 5-HT4R promoter activity in vitro
In chapter 4 we found that 5-HT4R mRNA expression was elevated in the PFC of Drd1a-Cre-CK2α KO as
well as Emx1-Cre-CK2α KO mice when compared to their WT littermates. To determine if changes occurred
cell autonomously in the cells lacking CK2α, we performed luciferase assays to study the activity of the
HTR4 promoter. We used HeLa cells, a cell line that has been previously used in 5-HT4R transcription
studies161 and cloned a 4 kb promoter fragment that corresponds to the region directly upstream of the first
exon of the HTR4, into a plasmid harboring the reporter gene (pGL3B). In order to modulate activity, we
inhibited CK2 pharmacologically with CX4945 or used shRNA targeting CK2α. Proof of successful CK2
knockdown was quantified by western blot (Figure 5.1C). Both pharmacological inhibition and knockdown
with shRNA enhanced HTR4 promoter activity by 34% and 31%, respectively (Figure 5.1A and Figure
5.1B). These results indicate that CK2α negatively regulates transcription of HTR4.
5.3.2. 5-HT4R-dependent signaling is controlled by CK2 activity in vitro
We tested if a post-transcriptional mechanism may also be at play under regulation of CK2. Like Dopamine
1 and A2a receptors, 5-HT4R is a G protein-coupled receptor. When activated, 5-HT4R signals via Gαs
stimulating cAMP production. We overexpressed HA-tagged 5-HT4R (HA-HTR4) in COS7 cells and
quantied cAMP production in the presence or absence of three different CK2 inhibitors: DMAT, TBB and
CX4945 (Figure 5.2A). Overexpression of HA-5HT4R increased cAMP concentration compared to empty
vector. All three inhibitors succeeded in elevating cAMP. TBB led to 1.6-fold increase, DMAT to a 1.9-fold
increase and CX4945 to a 2.3-fold increase in cAMP levels. Next, we selected inhibitor CX4945 to perform
a dose-response experiment. As the concentration of CX4945 was increased, cAMP levels were elevated
accordingly (Figure 5.2B). In addition, the increase in cAMP was completely blunted when COS7 cells were
co-treated with CX4945 and 5-HT4R inverse agonist, GR113808.
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Figure 5.1. The activity of the HTR4 promoter is increased after inhibition or knockdown of CK2 in
vitro. Luciferase assay using HeLa cells that were transiently transfected with either empty pGL3B vector
or vector containing the HTR4 5’UTR, after incubation with CX4945 (10µM) for 16 hours (A). Luciferase
assay using HeLa cells that expressed shRNA against CK2α or scrambled RNA and are transiently
transfected with either empty pGL3B vector or vector containing the HTR4 5’UTR (B) Quantifications of
three to four independent experiments (A,B) and western blot documenting CK2α knockdown from two
independent experiments (C). Graphs show the mean values ± S.E.M. Statistical analysis was performed
using one-way ANOVA: F(3,12) =61.84, P<0.0001 (A) F(3.8)=114.7, P<0.0001 (B) ; Bonferroni’s post tests
(*P<0.05, **P<0.01)
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To determine whether receptor endocytosis was affected by CK2, we performed biotinylation assays in
COS7 cells exogenously expressing HA-5-HT4R. When cells were treated with CK2 inhibitor CX4945, the
amount of membrane-localized receptor was 2.6-fold elevated while total levels of 5-HT4R remained
unchanged, indicating that CK2 promotes endocytosis/desensitization of the receptor (Figure 5.2C). Cotransfection of COS-7 cells with CK2α targeting shRNA also enriched 5-HT4R at the plasma membrane by
4.8-fold (Figure 5.2D). Furthermore, in response to serotonin, receptor endocytosis was prevented in the
presence of CX4945 (Figure 5.2E).
5.3.3. 5-HT4R-dependent signaling is controlled by CK2 activity in vivo
To confirm elevated 5-HT4R expression and signaling in vivo, we studied p42/44 ERK1/2 activation profile
in the mPFC of mice. P42/44 ERK1/2 is a downstream effector in the non-canonical 5-HT4R signaling
cascade that is activated and phosrphorylated following 5-HT4R stimulation162,163. We performed
immunohistochemical analysis of inner and outer layers of the pre- and infra-limbic regions of the mPFC
(Figure 5.3A) and observed a significant increase in both CK2α KO mice lines (Drd1a-Cre-CK2α and Emx1Cre-CK2α) in pERK positive cells (Figure 5.3A-G). Interestingly, Emx1-Cre-CK2α KO mice injected with
inverse agonist, GR113808 (0.1 mg/kg, i.p.), 30 min before perfusion, showed pERK levels that were
comparable to WT mice (Figure 5.3B and Figure 5.3C). These results indicate that the elevated pERK
signal is due to an increase in 5-HT4R expression and/or signaling. In the hippocampus of the Emx1-CreCK2α KO mice, where CK2α is also ablated, we did not observe differences in pERK signaling (Figure
5.3B), consistent with our previous qPCR findings.
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Figure 5.2. 5-HT4R-dependent signaling and expression is altered by CK2 in vitro. cAMP quantification
of lysates derived from COS-7 cells transiently transfected with HA-HTR4 or vector incubated with CK2
inhibitors for 3 hours (A) COS-7 cells transiently transfected with HA-HTR4 or vector were incubated for 3
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h with the indicated doses of CX4945 (B) or CX4945 (10µM) plus GR113808 (1µM) (C) before lysis and
cAMP determination. After CX4945 treatment, cells were biotinylated and strepatavidin-precipitated HAHTR4 divided by the signal form total lysate derived HA-HTR4 (D,E).COS-7 cells expressing shRNA
against CK2α or scrambled shRNA were transfected with HA-HTR4 . After 48 h, cells were lysed and
biotinylation experiment performed and quantified (F,G). Transiently HA-HTR4-transfected COS-7 cells
were incubated with CX4945, then stimulated with 10µM 5-HT for the indicated times. Biotinylation
experiments were performed and quantified (H). Graphs show the mean values ± S.E.M. Statistical analysis
for all panels is based on three independent experiments and performed using on-was ANOVA F(5,39)
=35.29, P<0.0001 (A); F(6,28)=113.3, P<0.0001 (B); F(4,45)=26.75, P<0.0001 (C) with Bonferroni’s post test;
or Student’s t-test (E,G,H). (*P<0.05,**P<0.01, ***P<0.001)
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Figure 5.3. 5-HT4R-dependent signaling is altered by CK2 in vivo. Scheme indicating the prelimbic and
infralimbic portions of the mPFC in a coronal mouse brain slice (A). Immunohistochemical analysis of mPFC
slices derived from male Emx1-Cre CK2α KO mice after 5 days of saline injection followed by acute
GR113808 (0.1 mg kg-1, i.p.), 30 min before perfusion. Slices were incubated with anti-pERK antibody
(T202/Y204)

(B)

Quantifications

of

the

prelimbic

(C)

or

infralimbic

(D)

mPFC

(N=9-11).

Immunohistochemical analysis of mPFC slices derived from male Drd1a-Cre-CK2α KO mice after 5 days
of saline injections. Slices were incubated with anti-pERK antibody (T202/T204) (E).Quantifications of the
prelimbic (F) or infralimbic (G) mPFC (N=5-6). Statistical analysis was performed using one-way ANOVA
and F(3,205)=8.33, P<0.0001 (C) F(3,151)=9.726, P<0.0001 (G), Bonferroni’s post-test or unpaired two-tailed
Student’s t-test (F,G) (*P<0.05,**P<0.01, ***P<0.001)
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5.3.4 Drd1a-Cre-CK2α KO mice are more susceptible to 5-HT4R agonist treatment
To investigate whether elevated 5-HT4R impacts on the behavioral level, we tested mice in TST or FST
after an acute dose of the 5-HT4R partial agonist, RS67333 (0.75mg/kg, i.p.) to Drd1a-Cre-CK2α mice
(Figure 5.4A and 5.4B). We observed that a single dose of agonist had no antidepressant effect on WT
mice but Drd1a-Cre-CK2α KO mice showed significantly reduced immobility in the TST (76% reduction
compared to baseline) and a trend towards reduced immobility in the FST. Suggesting increased
responsiveness to 5-HT4R agonist administration after CK2α ablation.

Figure 5.4. Responsiveness to 5-HT4R agonist is altered by CK2. Mice were given acute dose of
RS67333 (0.75 mg kg-1) 30 min before tail suspension test (A) or forced swim test (B). (N=8 WT, N=7 KO).
Graphs show the mean values ±S.E.M. Statistical analysis was performed using unpaired two-tailed
Student’s t-tests between treatments (**P<0.01)
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5.4. Discussion
To date, it is not known how 5-HT4R is regulated in the brain and so far, there is only information about the
promoter, derived from human atrial tissue56. It is also unknown which are the transcription factors involved
in 5-HT4R expression. Our experiments indicated that CK2 negatively regulates 5-HT4R transcription in the
PFC, being 5-HT4R the only 5-HT receptor upregulated in the PFC of the Drd1a-Cre-CK2α and Emx1-CreCK2α KO lines. In addition, we confirmed in vitro that the activity of the HTR4 promoter is enhanced when
CK2 is pharmacologically inhibited or knocked down as shown by luciferase assays. We hypothesize that
CK2 represses the HTR4 promoter by modulating the phosphorylation of a transcription factor that has not
been yet identified. This is not surprising, since CK2 has been previously described at partaking a role in
phosphorylating transcription factors essential for brain function like c-Fos or CREB 164,165 as well as brainspecific transcriptional regulators such as the AUTS2-Polycomb complex that is found disarrayed in
neuronal disorders166 or Olig2, a transcription factor necessary in oligodendrogenesis 167. Importantly, when
we performed this experiment in HEK293 cells or COS7 cells we did not observe any significant changes
in the activity of the HTR4 promoter, indicating tissue-specificity. Furthermore, at the post-translational
level, CK2 is important in the homeostasis of the receptor. Stimulation of 5-HT4R increasess cAMP levels
through activation of adenylyl cyclase. When CK2 is pharmacologically inhibited or knocked down in cells
exogenously expressing HA-HTR4 we observed an accumulation of cAMP. This enhanced increase in
cAMP levels response was 5-HT4R specific since co-treating the cells with 5-HT4R inverse agonist,
GR113808 and CK2 inhibitor prevented accumulation of cAMP.
As measured by western blot analysis in a biotinylation assay, total receptor levels were not altered after
inhibition or knockdown of 5-HT4R and only the amount of 5-HT4R at the plasma membrane was enhanced,
highlighting the importance of CK2 in receptor internalization.
In vivo, there was an enhanced activation of pERK through the non-canonical G protein-independent
pathway in the Drd1a-Cre-CK2α KO and in the Emx1-Cre-CK2α KO mice. 5-HT4R dependent activation
was confirmed by acute administration of 5-HT4R inverse agonist that normalized pERK levels to WT levels,
confirming an in vivo interaction between CK2 and 5-HT4R expression and/or signaling.
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Previous studies have proven the efficacy of RS67333 to induce an antidepressant-like response in mice
only after 3 days of treatment (as opposed to SSRI administration that require 2-3 weeks)47. We showed
that animals lacking CK2 were more sensitive to 5-HT4R agonist treatment and displayed an antidepressant
response after acute injection while WT littermates were non-responsive. These results indicate the
possible role of CK2 in potentiate the therapeutic efficiency of 5-HT4R agonist.
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Chapter 6
Defining the brain region mediating the phenotype
Adapted from 2018 publication: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like
behavior” Molecular Psychiatry (2018) 23, 872-882

6.1. Introduction
Much effort has gone into the identification of the brain region/s linked to the pathophysiology of depression
and antidepressant action. In addition to the hippocampus, the amygdala and the basal ganglia, the PFC
has been widely implicated168. Systemic 5-HT4R agonist administration and focal overexpression of 5-HT4R
in the mPFC increase the firing rate of DRN neurons 169 establishing a role for the 5-HT4R in the positive
feedback PFC-DRN loop which requires activation of 5-HT4R, firing of the PFC projection neurons and
release of 5-HT from the DRN onto target structures such as the PFC, hippocampus and others 2. In
humans, functional MRI studies have linked depressive behavior to hypometabolism of the mPFC while
deep brain stimulation of the mPFC resulted in clinical effects in treatment-resistant cases170,171.
Postmortem studies correlated MDD with reduced neuronal cell body size, atrophy of processes and a
reduction of glia in PFC172.
In rodents, exposure to chronic stress causes atrophy and neuronal glial loss in the PFC and the
hippocampus173,174. Decreased activity of the mPFC coincides with depression- and anxiety-like behavior
and correlates with the induction of ΔFosB, specifically in the prelimbic mPFC 170. Meanwhile,
antidepressant treatment leads to increased activity of cerebral cortex175. In addition, PFC neurons
projecting to the DRN are essential in mediating goal-directed behavior under stressful conditions since
optogenetic activation of these PFC neurons induced an antidepressant response by increasing mobility in
the FST176.
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In this chapter, we investigate whether the mPFC is the anatomical brain substrate involved in the
antidepressant- and anxiolytic-like phenotype presented in the CK2α KO lines. So far, we accumulated
evidence to propose the PFC as the key region mediating the phenotype. First, quantification of mRNA
expression of different serotonin receptors in the PFC, showed that only 5-HT4R was upregulated in both
Drd1a-Cre-CK2α KO and Emx1-Cre-CK2α KO mice. This upregulation was specific to the PFC and not
other brain regions like the striatum or the hippocampus, where CK2α was also ablated. Second, analysis
of the phosphorylation of p42/44 ERK1/2 in vivo, the non-canonical downstream effector of the 5-HT4R
signaling cascade, showed that Drd1a-Cre-CK2α KO and Emx1-Cre-CK2α KO mice presented enhanced
pERK positive cells compared to WT in the inner layers of the infra- and pre-limbic areas of the mPFC.
Furthermore, the inverse agonist GR113808 blunted this overactivation in the Emx1-Cre-CK2α KO mice
confirming that pERK enrichment in the mPFC is mediated through enhanced levels/activity of the 5-HT4R.
In order to fully determine the mPFC as the mediator of the antidepressant-like phenotype and discard any
possible developmental compensatory mechanisms of the CK2α KO lines, we targeted the mPFC of adult
mice using AAV9-mediated knockdown of CK2α or 5-HT4R as well as AAV9-mediated overexpression and
knockdown of 5-HT4R.
We hypothesize that knockdown of CK2α in the mPFC of adult mice would be sufficient to phenocopy the
behavior of the CK2α KO mice and expect to observe the same molecular changes in mPFC, namely,
enhanced pERK levels. In previous chapters, we established a role for CK2α as a negative regulator of 5HT4R expression and activity. We believe that the antidepressant-like phenotype was the result of 5-HT4R
upregulation in the absence of CK2α. Thus, we expect that overexpression of 5-HT4R in the mPFC will
recapitulate the phenotype of the CK2α KO lines. We also performed AAV9-mediated knockdown of HTR4
in the Drd1a-Cre-CK2α KO adult mice in order to abolish the phenotype. In addition, we quantified mRNA
expression of HTR4, CK2α and CK2β in a postmortem analysis of the PFC of patients that suffer from MDD
and compared to healthy individual to assess possible alterations of the expression profiles.
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6.2. Materials and methods
6.2.1. Viral Cre and 5-HT4 receptor expression
Male Mice received stereotactic injections of recombinant vector AAV9-GFP or AAV9-GFP-Cre
(AAV9.CMV.PI.eGFP.WPRE.bGH or AAV9.CMV.HI.eGFP-Cre.WPRE.SV40) bilaterally at two sites: AP
+1.9 ML +/-0.6, DV -2.2 and -2.7 using a Kopf mouse stereotactic frame and a micropump (WPI). The virus
was obtained from the Vector Core at the University of Pennsylvania. Per injection site, 1 μl of a viral
concentration of 3-4 x 1013 particles/ml was used. Three weeks post injection behavioral analysis was
performed over the course of 3 weeks and perfusions performed for IHC analysis using α-CK2 antibodies.
For overexpression of the 5-HT4 receptor we used AAV9 virus yielding to expression under the human
Synapsin

promoter linked to RFP expression via an Internal ribosomal entry site (IRES)

(AAV9.hSyn.HTR4.IRES.TurboRFP.WPRE.rBG and as control virus AAV9.hSyn.TurboRFP.WPRE.rBG)
both obtained from the Vector Core at the University of Pennsylvania. Per injection site, 1 μl of a viral
concentration of 6-7 x 1013 particles/ml was used. Bilateral injections into the mPFC were performed as
described for the AAV9-Cre virus above. Three weeks post injection behavioral analysis was performed
over the course of 3 weeks and perfusions performed for IHC analysis.
For knockdown of HTR4 we used AAV9 virus expressing shHTR4 or shScrambled and linked to the
expression of RFP under different promoters (AAV9.U6.shR.HTR4.CB7.CI.TurboRFP.SV40.delta E and as
control virus AAV9.HI.shRScr.CMV.TurboRFP.SV40) both obtained from the Vector Core at the University
of Pennsylvania. Per injection site, 1 μl of a diluted 1:10 solution from a viral concentration of 4.97 x 10 13
particles/ml was used. Bilateral injections into the mPFC were performed as described for the AAV9-Cre
virus above. Three weeks post injection behavioral analysis was performed over the course of 3 weeks and
dissections performed for qPCR analysis.
6.2.2.Human brain samples
Edited from Brice le Francois et al. A novel alternative splicing mechanism that enhances human 5-HT1A
receptor RNA stability is altered in major depression. J Neuroscience (2018)
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Postmortem brain tissues from subjects of both sexes were collected at autopsy at the Cuyahoga County
Medical Examiner's Office, Cleveland, OH. Protocol was approved for recruitment, tissue collection and
interviews of the next-of-kin by The Institutional Review Boards of the University of Mississippi Medical
Center and University Hospitals Case Medical Center. Written informed consent was secured from legallydefined next-of-kin. 15 depressed subjects met criteria for MDD and 9 one subject met criteria for
adjustment disorder with depressed mood. The Structured Clinical Interview for DSM-IV Axis I Disorders
was administered to knowledgeable informants for all subjects and diagnoses were made according to the
Diagnostic and Statistical Manual of Mental Disorders IV (American-Psychiatric-Association, 1994), as
described previously by Mahajan et al., 2018. All of the depressed subjects were experiencing depressed
mood in the last month of life, and none were diagnosed with a comorbid psychoactive substance use
disorder. Tissues were also sampled from psychiatrically normal control subjects that were matched for age
and post-mortem interval. Gray matter was dissected with a scalpel from frozen blocks of prefrontal cortex
and placed in an RNAse- and DNAse-free cold centrifuge tube on dry ice and then stored at -80° C. RNA
integrity number of 90% of the PFC samples was between 4 and 8, assessed using RNA6000 picochip on
2100 bioanalyzer (Agilent).
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6.3. Results

6.3.1. Focal knockout of CK2α in mPFC yields an anti-depressant-like phenotype
To investigate whether lack of CK2α in the mPFC is sufficient to mediate the antidepressed-like phenotype
we injected adeno-associated virus 9 (AAV9) leading to Cre and GFP expression in CKαfl/fl mice. We
assessed the loss of CK2α around the injection site by immunohistochemistry where cells lacking CK2α
co-express GFP and stainned for CK2α to confirm successful knockdown (Figure 6.1A). Mice injected with
control virus AAV9-GFP did not present loss of CK2α (Figure 6.1A). Behavioral assessment was performed
three weeks after injection. As hypothesized, mice injected with AAV9-Cre showed significantly reduced
immobility times in the TST (70% reduction) and FST (60.5% reduction) compared to AAV9-GFP injected
mice (Figure 6.1B and C). When placed in the EPM, AAV9-Cre mice spent more time (+93%) in the open
arms when compared to control animals (Figure 6.1D) and showed a reduced anhedonic-like behavior
when assessed their sucrose to water intake ratio in the SP test (2.8-fold) without changes in their drinking
behavior (Figures 6.1E). In the NSF test, AAV9-Cre animals presented a reduced latency to eat after a
period of 24 hours starvation but did not show an overall increase in food intake (Figure 6.1F and 6.1G).
Assessment of nesting behavior showed that AAV9-Cre animals failed in building a nest from cotton nestlets
within a period of 24 hours, as previously observed in the CK2α KO mice (Figure 6.1H). These results
clearly identify the mPFC as the region responsible of mediating the antidepressant- and anxiolytic-like
phenotype.
In chapter 4, we showed increased activation of pERK in cells of the inner layers of the mPFC of Drd1aCre-CK2α KO as well as Emx1-Cre-CK2α KO mice when compared to WT. We wanted to corroborate if
AAV9-Cre injected mice would also present an increased pERK activation in the mPFC.
Immunohistochemical analysis of brain sections revealed that compared to control injected mice there is a
significant increase of pERK levels in the inner layers of the mPFC (Figure 6.2) suggesting the involvement
of the same molecular mechanisms in the AAV9-Cre-mediated reduction of CK2α as in the CK2α KO mouse
lines, presumably, through upregulation of the 5-HT4R expression and/or activity.
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Figure 6.1. Focal KO of CK2α in mPFC leads to anti-depressant-like behavior in mice. Male CK2αfFl/fl)
mice were injected with AAV9-GFP or AAV9-GFP-Cre into the mPFC. Immunohistrochemical analysis of
slices derived from injected animals using anti-CK2α and anti-GFP antibodies, white bar=100 µm (A). Tail
suspension (B), forced swim test (C), elevated plus maze (D), sucrose preference test (E), noveltysupressed feeding test (F) food consumption after novelty supressed feeding test (G) and nesting behavior
(H) were performed with a cohort of these mice (N=10 for GFP, N=10 for GFP-Cre). Statistical analysis was
performed using unpaired two-tailed Student’s t-test (B,C,E,F,G) (*P<0.05) and one-way ANOVA,
F(3,35)=13.49. P<0.0001; Bonferroni’s post-tests (*P<0.05;**P<0.01; ***P<0.001) (D,H)
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Figure 6.2. ERK phosphorylation is enhanced in virally-mediated CK2α knockdown male mice.
Immunohistochemical analysis of PFC slices derived from mice injected with AAV9-GFP-Cre or control
mice injected with AAV9-GFP (A) Slices were incubated with anti-pERK antibody (T202/Y204).
Quantifications of the prelimbic mPFC are shown (B) (N=10 control, N=10 Cre). Statistical analysis was
performed using unpaired two-tailed Student’s t-test ( **P<0.01)
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6.3.2. Focal overexpression of the 5-HT4 receptor in mPFC yields an antidepressant-like phenotype.

If focal knockdown of CK2α in the mPFC drives the antidepressed-like phenotype due to upregulation of
the 5-HT4R, we hypothesized that focal overexpression of the 5-HT4R will mirror this behavior. We injected
AAV9-HTR4 bilaterally in the mPFC of WT animals leading to 5-HT4R overexpression and RFP expression
via an internal ribosomal entry site. We assessed correct site of injection by immunohistochemistry staining
for RFP (Figure 6.3A). Three weeks after surgery, we proceeded to behavioral assessment. We were able
to reproduce the phenotype in nearly all paradigms. AAV9-HTR4 mice presented reduced immobility times
both in TST and in FST (40.6% and 27% respectively) (Figure 6.3B and C). In the EPM, AAV9-HTR4
compared to control injected mice (AAV9-RFP) spent significantly more time (2.4-fold) in the open arms of
the maze, exhibiting a preference for this arm (Figure 6.3D). Although there is a trend towards a preference
for the consumption of sucrose solution compared to plain water this result was not significant (Figure 6.3E).
In the NSF test, AAV9-HTR4 presented a 3-fold reduced latency to eat when compared to control mice
(Figure 6.3F) without differences in the amount of food consumed (Figure 6.3G). As seen in the AAV9-Cre
animals, mice overexpressing the 5-HT4R in the mPFC, also failed to build a nest over a period of 24 hours
while control animals built a volcano-shaped nest during the same amount of time (Figure 6.3H). Taken
together, these data clearly show that focal overexpression of 5-HT4R in the mPFC is sufficient to
recapitulate the phenotype of the conditional CK2α KO mice and, more importantly, in mice with a virally
mediated focal knockdown of CK2α in the mPFC, and thus are in congruence with our hypothesis that the
phenotype in the CK2α KO animals stems at least in part from an upregulation of the 5-HT4R and its
signaling.
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Figure 6.3. Focal overexpression of 5-HT4R in mPFC leads to antidepressant-like behavior in mice.
Male CK2α(fl/fl) mice were injected with AAV9-RFP and AAV9-HTR4 into the mPFC. Immunoshistochemical
analysis of slices derived from injected animals, white bar=100 µm (A). Tail suspension test (B) Forced
swim test (C) Elevated plus maze (D) Sucrose preference test (E) and novelty supressed feeding test (F)
food consumption (G) and nesting score (H) were performed with a cohort of these mice (N=10 Control,
N=9 HTR4 overexpressors). Statistical analysis was performed using unpaired two-tailed Student’s t-test
(B,C,E,F,G,H) (*P<0.05, ****P<0.0001) and one-way ANOVA: F(3,40)=13.24, P<0.0001; Bonferroni’s posttest (**P<0.01, ****P<0.0001) (D)
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6.3.3 Focal knockdown of 5-HT4R in the Drd1a-Cre CK2α knockout mice
Our CK2α KO mice present an antidepressed and anxiolytic-like phenotype. When we studied their mRNA
expression profiles using qPCR we found that, from all the 5-HT receptors tested, only the 5-HT4R was
upregulated specifically in the PFC . We injected AAV9-mediated shRNA targeting HTR4 and receptor gene
expressing RFP in the Drd1a-Cre-CK2α KO mice to investigate whether knockdown of HTR4 would be
sufficient to abolish the phenotype of the Drd1a-Cre-CK2α KO mice. We assessed correct site of injection
by immunohistochemistry staining for RFP. We accomplished a 30% reduction in HTR4 mRNA of mPFC
tissue as shown by quantitative RT-PCR quantification (Figure 6.4A); based on our previous qPCR results
showing that conditional CK2α KO mice present an approximate 30% upregulation of HTR4 in the PFC,
AAV9-mediated knockdown should be sufficient to render 5-HT4R expression to WT levels.
Three weeks after surgery we proceeded to behavioral characterization. While in the WT group knockdown
of HTR4 did not affect behavior in the FST, in the Drd1a-Cre-CK2α KO mice group, immobility time was
significantly elevated after shRNA mediated knowckdown of HTR4 (Figure 6.4B). We did not observe any
significant difference in EPM, TST, NSF or SP.
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Figure 6.4. Knockdown of HTR4 in the mPFC partially rescues the antidepressant-like phenotype.
Quantitative RT-PCR performed on PFC tissue from male WT mice injected unilaterally with AAV9-shHTR4-RFP (N=5) (A) Forced swim test (N=6 AAV9-Control WT, N=6 AAV9-sh-HTR4 WT, N=5 AAV9Control KO, N=7 AAV9-sh-HTR4 KO) (B). Graphs show mean values ± S.E.M. Statistical analysis was
performed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01).

6.3.4. 5-HT4R, CK2α and CK2β mRNA levels are unaltered in the human PFC of depressed patients.
In this chapter we clearly identified that alteration of CK2α as well as 5-HT4R overexpression in the mPFC
led to changes in mood-related behaviors. Knockdown of CK2α or overexpression of 5-HT4R in mPFC
decreased depressive- and anxious-like behavior in mice. We investigated if unmedicated patients that
suffered MDD, presented changes in mRNA expression profiles of HTR4, CK2α and CK2β. Our results did
not indicate the presence of significant differences in HTR4, CK2α or CK2β levels between the MDD group
and healthy individuals (Figure 6.5A) suggesting that downregulation of HTR4 receptor or changes in CK2α
or CK2β do not participate in the etiology or expression of MDD.
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Figure 6.5. HTR4, CK2α and CK2β mRNA levels are unaltered in MDD patients. Quantitative RTPCR performed on human PFC tissue (A,B,C) (N=12 Control, N=11 MDD). Graphs show the mean
values± S.E.M.. Statistical analysis was performed using unpaired two-tailed Student’s t-test comparing
different probes between conditions. (A)
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6.4. Discussion
AAV9-mediated focal knockdown of CK2α through Cre expression in the mPFC was sufficient to mirror the
phenotype observed in the CK2α KO lines, the Drd1a-Cre-CK2α (ablation of CK2α in striatum and cortex)
and the Emx1-Cre-CK2α (ablation of CK2α in hippocampus and cortex). These results highlight the mPFC
as the major region responsible for driving the antidepressant-like phenotype. Since AAV9-mediated
injection is performed in adult mice, we corroborated that the phenotype is caused by the absence of CK2α
and not by developmental changes induced by the embryonic KO of the CK2α KO lines associated with
pre- or perinatal Cre expression that occurs in our mouse lines. Based on these findings, we therefore
propose CK2α as a novel upstream player in the PFC-DRN loop regulating 5-HT4R expression specifically
in the mPFC.
Previous studies indicate that subchronic administration of 5-HT4R agonist result in an antidepressant
response51. We are the first ones to show that it is sufficient to focally overexpress 5-HT4R in the mPFC to
generate a robust antidepressive/anxiolytic-like phenotype. The behavioral outcome to focal
overexpression is in accordance with the fact that 5-HT4R expression in glutamatergic mPFC pyramidal
neurons regulate 5-HT levels in the DRN through a positive mPFC-DRN feedback loop169 and provides
further rationale that the effect of CK2 is primarily driven through altered expression/signaling of the 5HT4R.
Our results show that shRNA-mediated knockdown of 5-HT4R in the mPFC of the Drd1a-Cre-CK2α KO
partially abolished the antidepressant/anxiolytic-like phenotype in the FST, where Drd1a-Cre-CK2α KO
animals expressing shRNA-HTR4, remained significantly more time immobile than Drd1a-Cre-CK2α KO
animals expressing scrambledRNA vector. The limitations of this approach should not be discarded. First,
due to the lack of effective antibodies against 5-HT4R, we could only assess 5-HT4R knockdown through
quantitative RT-PCR. Although we achieved a 30% transcript reduction we cannot quantify the amount of
translated protein reduction. In addition, due to breeding problems, we could not perform these experiments
in the Emx1-Cre-CK2α animals which did not present a hyperlocomotive phenotype. The hyperlocomotion
of the Drd1a-Cre-CK2α KO animals stems from the upregulation of the D1R in the striatum124. Thus, we did
not expect knockdown of HTR4 to abolish hyperlocomotion. This implies that it will be unclear to discern
the contribution of enhanced motor activity from the antidepressive-like phenotype when comparing Drd1a-
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Cre and the WT groups in those tests that depend on locomotor activity. Nevertheless, partial rescue
indicates that part of the phenotype of the CK2α KO mice is purely mediated by the 5-HT4R in the mPFC.
On the other hand, if our results are not limited by poor protein expression or hyperlocomotion, it is important
to consider the possibility that even though upregulation of 5-HT4R is responsible of mediating the
antidepressant-like phenotype, a reduction of 5-HT4R levels might not reverse this behavior due to
compensatory mechanisms. For example, we showed that, in patients that suffered MDD, levels of HTR4,
CK2α and CK2β are unaltered in the PFC when compared to healthy individuals. Taken all together we can
conclude that while increased levels/signaling of 5-HT4R in the mPFC generate an antidepressant-like
response, the reversed phenotype, depressive-like behavior is only partially caused by a reduction in the
receptor levels.

75

Chapter 7
Neurogenesis, spatial learning and working memory

7.1 Introduction
7.1.1 Adult Neurogenesis
The hippocampus (HPC) is a major structure involved in cognitive processes with the ability of generating
newborn neurons and its functionality is divided across the dorsoventral axis 154,177. In mice, the dorsal HPC
(dHPC), posterior HPC in humans, is responsible for cognition and spatial learning as well as for encoding
contextual memory178-182. The ventral HPC (vHPC), anterior HPC in humans, is responsible of regulating
mood, sociability, stress resilience180,181 and recently it has been discussed its implication in the
pathophysiology of anxiety-related behaviors183-187.
The dentate gyrus (DG) of the hippocampal formation is one of the few structures capable of generating
newborn cells in the adult brain across different species. In humans, neurogenesis is still today a topic of
controversy and in 2018, two different studies published colliding results. In the first study, Sorrells et al.,
using immunohistochemistry analysis of post-mortem brains concluded that, after childhood, neurogenesis
events become undetectable. In the second study, Boldnini et al., using incorporation of tracers that label
DNA of newborn neurons, concluded that neurogenesis is present during the whole human lifespan. An
extensive review can be found in 188 where different variables of both studies are discussed such as fixation
method, post mortem delay and selected labeling technique, etc., concluding that adult neurogenesis is
most likely to be relevant throughout lifespan in consistency with animal studies.
Neurogenesis has been detected across all species except for aquatic and some flying animals 189. In mice,
neurogenesis is required to mediate the effects of antidepressants and has become a marker of
antidepressant action since administration of SSRIs significantly increased neurogenesis in the DG of the
HPC in 2-3 weeks, a timeframe that coincides with the onset of action of antidepressant drugs49,190-192. In
addition, administration of 5-HT4R inverse agonist, RS67333, generated an antidepressant- like response
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in mice only after 3 days of administration together with molecular changes characteristic of antidepressanttreated animals namely, increased pCREB, desensitization of 5-HT1B autoreceptors and ultimately,
enhanced neurogenesis46,51. There is also a distinction in the role of neurogenesis across the dorso-ventral
axis since adult-born neurons in the DG of the dHPC are required for timely acquisition of contextual
discrimination whereas neurogenesis in the vHPC is required to mediate the effects of fluoxetine under
certain conditions193.
7.1.2. 5-HT4R and CK2 in learning and memory
Cognitive impairments have been associated with MDD194,195 such as memory and attention196,197 and
antidepressant drugs that target the monoaminergic system have been unsuccessful in reversing such
cognitive deficits198,199. Administration of 5-HT4R inverse agonist, RS67333, in rodents, not only has been
a promising candidate as a fast-acting antidepressant drug but also as a new treatment for the cognitive
deficits that accompanied MDD200.
The PI-3K/Akt pathway has been involved in the formation of long-term memory201,202. CK2 partakes a role
in the PI-3K/Akt signaling cascade with a high degree of cross-regulation, for example, by phosphorylating
Akt. It has been shown that CK2 activity in the CA1 region of the hippocampus decreases spatial memory
formation203 although surprisingly, it is also involved in the induction of LTP204.
In this chapter, given the antidepressant-like phenotype of the AAV9-Cre animals as well as the AAV9HTR4 overexpressing mice, we analyzed neurogenesis across the dorso-ventral axis of the HPC. We are
interested in understanding the role of the mPFC in exerting control over the generation of newborn
neurons. Since there is not a direct projection mPFC-HPC, our hypothesis is that, increased neurogenesis
would be mediated by: a) the DRN through a mPFC-DRN-HPC loop where enhanced activity of 5-HT4R in
the mPFC increases 5-HT tonus thus controlling firing at the DRN projecting to the HPC and thus enhancing
neurogenesis or b) Neurogenesis is increased through an unknown target controlled by CK2 and
independent of the 5-HT4R. Given the role of the 5-HT4R in restoring memory and learning deficits in mouse
models of anxiety and depression in rodents as well as the role of CK2 in impairing spatial memory
formation, we aim to identify whether knockdown of CK2α as well as overexpression of 5-HT4R in the mPFC
would play a role in cognitive processes.
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7.2 Materials and methods
7.2.1 BrdU incorporation and Immunohistochemistry
Mice were injected intraperitoneally with 5'-bromo-2'-deoxyuridine (BrdU) 50mg/kg in saline solution twice
daily for four days before intracardial perfusion with 4% PFA. Brains were transferred to 30% sucrose
solution until sunk and sliced coronally at 30µm thickness. One out of 6 slices were selected across the
whole hippocampus for immunostaining. A total of 10 slices per animal were selected for the dorsal
hippocampus and 10 slices per animal for the ventral hippocampus. Slices were washed 3x with PBS for
10 min, Incubated 10 min with HCl 1M at 4 degrees, then incubated for 20 min with HCl 2M at 37ºC,
permeabilized for 10 min with PBS-T 0.05%, blocked with horse serum for 2 hours at room temperature
and incubated with Brdu anti-rat primary antibody overnight at 4 degrees. The next day, slices were washed
3x with PBS for 10 min and incubated with secondary antibody Alexa Fluor 488 anti-rat for 2 hours at room
temperature, washed again 3x with PBS for 10 min and mounted onto coverslides with Vectorshield
mounting agent. Imaging was performed with a Zeiss LSM710 laser-scanning confocal microscope.
Quantification performed using Image J software.
7.2.2 Y-maze Spontaneous Alternation
A Y-shaped maze with three black, opaque plastic arms at a 120° angle from each other was used. Mice
are placed at the end of one Y-maze arm and allowed to freely explore the three arms for 8 minutes. The
number of arm entries and the number of triads were recorded in order to calculate the percentage of
alternation between the 3 arms. An entry occurred when all four limbs were within the arm.
7.2.3 Y- maze Spatial recognition
A Y-shaped maze with three black, opaque plastic arms at a 120° angle from each other was used. In
phase 1, one arm was blocked (randomly) and mice were allowed to explore for 5 min. In phase 2, the
blocked arm was opened and mice were allowed to explore for 3 minutes, starting one hour after termination
of phase 1. The percentage of time spent in either novel versus habituated arms was determined and
plotted. Mice spending less than 10% in one arm were excluded.
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7.2.4 Novel object recognition
Mice were placed in the corner of an Open field arena with two identical objects placed in opposite corners
of the subject position for 10 minutes (familiarization phase). Mice were placed a second time in the open
field arena. In this situation, with one of the familiar objects is removed and a novel object is introduced.
Mice were allowed to freely explore the arena for 10 min (test phase). The amount of time spent near both
objects was quantified. Mice were considered to explore the object when directing the nose at a distance >
2 cm to the object and/or touching it with the nose facing the novel object and sniffing the object. Behaviors
like climbing the object, turning around close to the object and sitting on the object were not quantified as
exploration.
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7.3 Results
7.3.1. Neurogenesis in the vHPC is enhanced in the AAV9-Cre mPFC mice but not in the AAV9-5-HT4R
mice
After injection of AAV9-Cre or AAV9-HTR4 as described in chapter 5, mice were injected with BrdU for 3
days twice daily before perfusion. BrdU is an exogenous, synthetic nucleoside analog to thymidine. When
injected intraperitoneally, BrdU is incorporated during DNA synthesis205 . As a result, newborn cells can be
detected by screening the presence of BrdU. Quantification of BrdU positive cells in the dorsal and the
ventral hippocampus separately indicates that AAV9-Cre animals presented enhanced amount of newborn
neurons in the DG of the vHPC but not in the DG of the dHPC. (Figure 6.7A and B).
Surprisingly, animals overexpressing the 5-HT4R in the mPFC did not show any significant change in the
amound of BrdU+ cells in the DG of the vHPC nor the dHPC when compared to control animals (Figure
7.2A and B).
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Figure 7.1. Neurogenesis is enhanced in the vHPC of AAV9-Cre mPFC animals. Immunohistochemical
analysis of of vHPC (top) and dHPC (bottom) derived from AAV-GFP-Cre mice or control mice injected with
AAV9-GFP (A) Slices were incubated with anti-BrdU antibody. Quantifications of BrdU+ cells are shown for
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the ventral DG (B) or the dorsal DG (C) (N=10 control, N=10 Cre). Graphs show mean values ± S.E.M.
Statistical analysis was performed using unpaired two-tailed Student’s t-test (*P<0.05)

Figure 7.2. Neurogenesis is not altered

in the HPC of AAV9-HTR4 mPFC animals.

Immunohistochemical analysis of of vHPC (top) and dHPC (bottom) derived from AAV9-RFP-HTR4 mice
or control mice injected with AAV9-RFP (A) Slices were incubated with anti-BrdU antibody. Quantifications
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of BrdU+ cells are shown in the ventral DG (B) or the dorsal DG (C) (N=10 control, N=10 Cre). Graphs
show mean values ± S.E.M. Statistical analysis was performed using unpaired two-tailed Student’s t-test.

7.3.2 Focal expression of AAV9-Cre-GFP in the mPFC results in a decreased performance in memory tasks
but not overexpression of AAV9-HTR4-RFP
Expression of AAV9-Cre in the mPFC of WT-CK2fl/fl animals had an effect in the hippocampus by
significantly increasing neurogenesis when compared to control animals. Next, we wanted to study the
presence of any phenotype associated with dHPC cognitive function. For this purpose, we performed three
different behavioral assessments of spatial learning/ working memory: Novel object recognition (NOR),
Spatial recognition (SR) and Spontaneous alternation (SA) (the later two take place using a Y-maze).
The Y-Maze SA paradigm is based on the intrinsic tendency of rodents to explore a novel environment.
When placed in the Y-Maze, mice are more likely to enter the least visited arm and as consequence, to
alternate visits between the three arms of the maze. A mouse with impaired working memory will fail to
alternate such visits. When we quantified the number of arm alternations, AAV9-Cre mice only showed a
trend towards decreased number of correct alternations when compared to controls (Figure 7.3A).
The SR task involves two phases. In phase one, one arm is blocked and the mouse is allowed to freely
explore. After an hour interval, the mouse is placed again in the Y-maze and is able to explore the entire
maze. AAV9-Cre mice spent less time in the novel arm than control animals (Figure 7.3B) indicative of an
impairment in spatial memory. In the NOR task, time spent exploring a familiar object and a novel object is
quantified after a habituation phase to the familiar object. While control mice preferred to spend more time
exploring the novel object, AAV9-Cre did not have a preference (Figure 7.3C) suggesting an impairment in
working memory.
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Figure 7.3. Spatial and working memory are impaired in AAV9-Cre mice. Percentage of correct
alternations in Spontaneous alternation test (A) and total number of entries (B). In the Novel object
recognition task, relative time spent exploring novel and familiar objects (C) relative time spent exploring
two identical (familiar) objects in the habituation phase (D) and percent of time spent in the novel arm of
the Y-Maze in spatial recognition test (E). (N=10 control, N=10 Cre). Graphs show mean values ± S.E.M.
Statistical analysis was performed using unpaired two-tailed Student’s t-test (A-E)( *P<0.05, **P<0.01)

84

When we used the same paradigms to assess the spatial learning and working memory of AAV9-HTR4RFP, we did not see any difference in the number of alternations between groups in the SA task (Figure
7.4A) or in the time spent in the novel arm of the Y-maze in the SR test when compared to control-injected
littermates (Figure 7.4B). In the NOR test, AAV9-HTR4 mice preferred to spend time in the vicinity of the
novel object, the same behavior observed in the corresponding control animals (Figure 7.4C). This suggests
that overexpression of 5-HT4R in the mPFC did not result in any disturbances in spatial learning and working
memory.
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Figure 7.4 Spatial and working memory are intact in AAV9-RFP-HTR4 mice. Percentage of correct
alternations in Spontaneous alternation test (A) and total number of entries (B), relative time spent exploring
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novel and familiar objects (C) relative time spent exploring two identical (familiar) objects habituation phase
(D) in the novelty suppressed feeding test and percent of time spent in the novel arm of the Y-Maze in
spatial recognition test (E). (N=10 control, N=10 Cre). (N=10 control, N=10 Cre). Graphs show mean values
± S.E.M. Statistical analysis was performed using unpaired two-tailed Student’s t-test (A-E) (*P<0.05)

7.4 Discussion
Neurogenesis has become a marker of antidepressant action since in mice, SSRIs are able to enhance
neurogenesis in 2-3 weeks, timeframe that corresponds with the onset of antidepressant efficacy190-192.
Given the antidepressant-like behavior of the AAV9-Cre and the AAV9-HTR4 animals, we were interested
in determining whether there was increased neurogenesis in the DG across the dorso-ventral axis of the
HPC mediated through the mPFC.
Interestingly, the AAV9-Cre animals presented significantly higher newborn neurons, as analyzed by BrdU
incorporation, than control animals in the vHPC while the increase in the dHPC was not significant. This is
consistent with an antidepressant-like behavior since the vHPC and not the dHPC is responsible for
regulating emotion and anxiety-like responses7,183,185-187,206-209. Next, we used three different tests that
engaged the HPC to assess if there were any performance differences in working memory and spatial
learning. We did not observe a significant difference in the SA test. Nevertheless, AAV9-Cre mice
performed worse than their control littermates in the NOR and SR tests. The NOR task is widely used to
assess memory alterations. However, it is also anxiety sensitive. The introduction of a novel object can
cause an anxiety-like response in mice leading to an avoidant behavior. Since we are certain that AAV9Cre animals present a strong anxiolytic-like phenotype, we discarded the differences in behavior due to
increased anxiety, but rather to an altered working memory.
When we quantified neurogenesis in the AAV9-HTR4 animals, we were surprised for two main reasons.
First, because AAV9-HTR4 animals presented a very strong anxiolytic-like phenotype when tested in the
NSF. This particular test is neurogenesis dependent since mice irradiated using X-Ray targeting the HPC
were unable to respond to antidepressant treatment or 5-HT4R agonist, RS6733351 indicating that
neurogenesis is needed to mediate an antidepressant response. Nevertheless there are some differences
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to take into consideration such as, the use of a mouse model of depression (animals were long-term
exposed to corticosterone) and received 5-HT4R agonist treatment or fluoxetine. Interestingly, our results
suggest that, even though RS67333 administration enhances neurogenesis when compared to saline
treated animals, this boost in neurogenesis might not be needed and just basal neurogenesis is sufficient
to mediate the antidepressant response since AAV9-HTR4 animals did not present enhanced neurogenesis
when compared to controls, yet displayed an anxiolytic-like behavior in the NSF. Second, because AAV9Cre animals did in fact present increased neurogenesis, we hypothesized that this enhancement was due
to elevated 5-HT tonus in the DRN mediated through the mPFC rather than some mechanism involving a
direct projection mPFC-HPC. Overexpressing 5-HT4R exerts ontrol of 5-HT concentration in the DRN45 but
this did not mediate neurogenesis in the HPC. When mice were tested in the same memory tasks as the
AAV9-Cre animals, there were no significant differences in the performance between groups.
From these results, we do not aim to link neurogenesis and performance in hippocampal memory tasks.
Indeed, cognition is affected by the dHPC and not the vHPC, where we did not observe any difference in
neurogenesis. Given these results we suggest that knockdown of CK2α in the mPFC most likely regulates
one or more unknown targets independent of 5-HT4R that are responsible to mediate the altered spatial
and working memory in AAV9-Cre rather than just an increase in serotonin, as first thought. The
determination of this unknown candidate is over the scope of this work.
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Chapter 8
Conclusions

A lot of effort has been placed in the understanding of the pathophysiology of MDD and antidepressant
action. The origin of MDD is unknown and the huge symptomatic heterogeneity of MDD makes its study
exceptionally challenging. As an added difficulty, comorbidity with other diseases such as anxiety disorders
is the norm and not the exception5.
Currently, antidepressant drugs that target the monoaminergic system are the most common treatment for
MDD. Unfortunately, they are only effective in 1/3 of the population and present a delayed onset of
action23,24. Recently, agonists of the 5-HT4R have emerged as potential fast acting antidepressant
candidates. Mice treated with 5-HT4R agonist, RS67333 present an antidepressant-like response only after
3 days of treatment in contrast with SSRIs that require 2-3 weeks of chronic administration before the onset
of therapeutic efficacy47. What is still not known the regulators of 5-HT4R expression and activity in the brain
responsible of mediating the antidepressant-like response.
This dissertation identifies CK2 as a novel regulator of 5-HT4R. In chapter 4, we presented an interesting
phenotype in the conditional CK2α KO mice, the Drd1a-Cre-CK2α which lacks CK2α in striatum and cortex.
When mice were tested in a battery of paradigms to assess anxiety- and depressive-like behaviors, Drd1aCre-CK2α KO mice, displayed a phenotype reminiscent of antidepressant treated animals, even in a task
that is only sensitive to chronic antidepressant treatment, the NSF 51. Unfortunately, this mouse line also
presented a hyperlocomotive phenotype and for this reason, we decided to corroborate the results found
in the Drd1a-Cre-CK2α in a second mouse line that was not hyperlocomotive. We generated the Emx1Cre-CK2α and we were able to reproduce the phenotype in all tests in male cohorts as well as in females.
Given this robust antidepressed- and anxiolytic-like phenotype, we investigated the underlying molecular
mechanisms. Since both CK2 KO lines tested were reminiscent of antidepressant treated animals, we
hypothesized that the serotonergic system or the norepinephrine system might be altered, which
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correspond to the main targets of antidepressant drugs. Drd1a-Cre-CK2α KO mice were more responsive
to both TCA imipramine that targets the serotonergic as well as the norepinephrine system and SSRI
fluoxetine that targets specifically the serotonergic system. This result is particularly interesting for two
reasons. In the first place, because KO mice responded to TCA and SSRI at a lower dose when WT mice,
and because the effect of chronic administration of fluoxetine was stronger in KO mice than in WT as
measured by the fold reduction in the immobility time when comparing untreated animals with 15 days
fluoxetine-injected mice. It will be interesting to test if co-administration of low dose of CK2 inhibitor and
SSRI or TCA will render both a more dramatic antidepressant-like response than the antidepressant drug
alone, if given low dosage of both there is an improvement in the side effects and if the onset of therapeutic
efficiency is reduced. Our experiments suggest that this combination might work as a potential fast acting
antidepressant. CX4945 has been proven to be well tolerated when orally administered in low doses and
reducing the dose of SSRIs or TCA might be beneficial to avoid the unwanted side effects of this drugs. In
our opinion, pharmacological inhibition of CK2 will boost the therapeutic response of current
antidepressants.
Since Drd1a-Cre mice are susceptible to SSRI in addition to TCA, the serotonergic system was our prime
candidate of interest. To study possible alterations in the serotonergic system of the CK2 KO mice, we
chose a panel of receptors based on their expression profiles coinciding with the regions of CK2α KO, and
we found the 5-HT4R, and no other 5-HT receptor upregulated specifically in the PFC and not other brain
regions where CK2 was also absent, for example, striatum in Drd1a-Cre-CK2α and hippocampus in Emx1Cre-CK2α, which indicates that CK2 negatively regulates 5-HT4R expression a the transcriptional level.
Chapter 5 further investigates the molecular mechanisms by which CK2 regulates 5-HT4R. Specifically, we
wanted to see if the transcriptional control extended to an enhancement of the HTR4 promoter activity and
if a post-translational mechanism was involved as well. To further characterize CK2’s transcriptional
regulation of HTR4, we assessed how CK2 modulates the activity of the HTR4 promoter and found in
luciferase assays that when CK2 is pharmacologically inhibited or knocked down in vitro, the activity of the
HTR4 promoter is increased. This experiment was performed in three different cell lines. We were only able
to see an enhanced activity of the HTR4 promoter in HeLa cells, a cell line previously reported in the study
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of the 5-HT4R promoter161 while this was not the case when using COS7 or HEK293 cells, indicating that
CK2 might increase HTR4 promoter activity tissue- and species-specifically. Very little is known about the
HTR4 promoter across tissues and we just have rudimentary knowledge derived from human atrial tissue
and placenta56,57. We have preliminary evidence that the CK2-dependent promoter element lies within a
500 bp sequence upstream of the first transcribed exon and will continue to identify the minimal sequence
necessary for regulation by CK2. We hypothesize that CK2, through phosphorylation, recruits a
transcriptional repressor to the HTR4 promoter. It would be interesting in future studies to determine this
factor and its binding region on the HTR4 gene.
In addition to a tissue and brain region specific transcriptional regulation, we also found a post-translational
regulation at play. Pharmacological inhibition or shRNA-mediated knockdown of CK2 in cultured cells
enhanced the activity of the 5-HT4R by increasing cAMP levels in vitro in a dose dependent manner and
also enriched the expression of the 5-HT4R at the plasma membrane. This effect was not due to enhanced
transcription of the receptor since we used HTR4 expressed exogenously under a CMV promoter and
controlled for expression by western blotting experiments. We hypothesized that CK2 is responsible for
mediating endocytosis of 5-HT4R. Similarly, Rebholz et al previously found that CK2 negatively regulates
D1R internalization as well as A2A receptor, another Gαs coupled receptor, but not other GPCRs coupled
to Gi/o125. The main hypothesis is that there is a direct interaction between CK2 and Gαs, most likely through
an accumulation of CK2 by the membrane and adjacent to the GPCR complex. This interaction needs the
β subunit in agreement with previous studies suggesting a role for CK2β in the recruitment of the CK2
holoenzyme to substrates, such as the transmembrane receptor CD5210. Nevertheless the substrate
responsible for CK2 mediated –Gαs-coupled receptor signaling is not known.
Unfortunately, available 5-HT4R antibodies lack specificity and we could not assess the protein expression
of 5-HT4R in vivo in a straightforward fashion. Instead, we indirectly tested the phosphorylation status of
ERK1/2, a downstream effector of the 5-HT4R signaling cascade163. Chapter 4 RT-PCR experiments
indicated that, in the mouse brain of the CK2 KO lines, the upregulation of 5-HT4R was specific to the PFC.
When analyzing the PFC of both WT animals and CK2 KO mice using immunohistochemical analysis, we
observed an enhanced number of pERK positive cells in the pre- and infra- limbic areas of the mPFC in
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both CK2 KO mouse lines (Drd1a-Cre-CK2α and Emx1-Cre-CK2α). Following 5-HT4R stimulation, ERK is
phosphorylated Src- dependently211. Interestingly, administration of 5-HT4R antagonist in the Emx1-CreCK2α, GR111808, decreased pERK+ cells to WT levels indicating that overactivation of pERK is 5-HT4Rmediated. As expected, we did not observe pERK differences in the HPC, where CK2α was also ablated.
It is worth discussing that, after noxious stimulation and/or injury, ERK activation is induced after a minute
and pERK quantification has been used as a marker neuronal marker of pain hypersensitivity212,213. For this
reason, we injected all animals with saline solution for a week before perfusion to habituate them to the
injection stress.
Given the transcriptional and post-translational upregulation of 5-HT4R we wanted to investigate whether
CK2 mice would respond to 5-HT4R agonist treatment. In agreement with our hypothesis, Drd1a-Cre-CK2α
were more sensitive to inverse 5-HT4R agonist, RS67333, than their WT litermates in the TST. While WT
mice did not respond to an acute dose of RS67333, immobility time of the Drd1a-Cre-CK2α KO was
significantly reduced. 5-HT4R has been interesting in the context of new fast acting antidepressants since
3 days of 5-HT4R administration is able to render an SSRI-like response bothe behaviorally and molecularly
by: enhanced levels of pCREB, increased neurogenesis and increased firing of postsynaptic 5-HT1A in the
hippocampus and desensitization of 5-HT1A autoreceptors

47.

In the same fashion we found with

antidepressant drug treatmnet, CK2 KO mice were also more responsive to RS67333, suggesting low dose
co-administration of CK2 inhibitor together with 5-HT4R agonist a promising pharmacological approach to
a rapid antidepressant response with less side effects.
Taken all together, chapter 5 provides evidence that CK2 negatively regulates 5-HT4R signaling in vitro, by
enhancing both 5-HT4R activity and expression at the plasma membrane, and in vivo, as seen by increased
pERK in mPFC of CK2α KO mice, and behaviorally, due to their higher susceptibility to 5-HT4R agonist
treatment.
Chapter 6 confirms the mPFC as the region mediating the antidepressant/anxiolytic like phenotype. For this
purpose, we knocked down CK2 in the mPFC of adult mice using adeno-associated virus. We were able to
completely mirror the phenotype found in the CK2 conditional KO lines in all tests. These results established
the mPFC as the region responsible of mediating the phenotype. Furthermore, we overexpressed 5-HT4R
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in the same region and we were also able to phenocopy the behavior, providing a rationale to confirm that
CK2, through upregulation of 5-HT4R is responsible of mediating the phenotype.
In addition, we hypothesized that knockdown of 5-HT4R in the mPFC, might be sufficient to abolish the
antidepressed/anxiolytic-like phenotype of the Drd1a-Cre-CK2α. After adeno-associated virus injection of
shHTR4 or shscrambled into the mPFC, we could partially rescue the depressive-like behavior in the FSTof
the Drd1a-Cre-CK2α KO injected with AAV9-shHTR4 when compared to the Drd1a-Cre-CK2α KO injected
with scrambledRNA while there was not an increase in the immobility time between the WT group (AAV9shHTR4 and AAV9-scrambledRNA). Other tests, such as TST, EPM, SP or NSF did not show any effect
of HTR4 knockdown. In this approach, there are some technical issues that could be at stake. First, we
were only able to quantify knockdown after viral injection by RT-PCR. Even though we were able to achieve
a 30% reduction of HTR4 levels of AAV9-shHTR4 injected animals when compared to the control side, we
had no control over how much this transcript reduction translates to protein expression. Furthermore, RFP
signal in the mPFC was used to select the animals that will be considered for quantitative behavioral
analysis which provided information about the injection quality, nevertheless, assessment of RPF might be
misleading since, in the construct used, shHTR4 and RFP expression are driven under different promoters.
Nevertheless, RFP stainning was still a good indicator of the injection site quality. Second, increasing the
expression might be challenging. We performed several titrations of the virus and found that 1:10 dilution
gave the best knockdown. Undiluted shRNA did not yield better expression and it can actually induce
toxicity due to the depletion of the host miRNA processing machinery214. In addition, the Drd1a-Cre-CK2α
KO is hyperlocomotive which does not render this mouse line an ideal candidate. Knocking down HTR4 in
the mPFC would not be sufficient to normalize locomotion to WT levels. The hyperlocomotive phenotype
most probably originates from upregulation of the D1R in the striatum due to CK2 depletion since
administration of D1R antagonist, SCH23390, normalizes locomotion to WT levels in the Drd1a-Cre-CK2α
KO mice124. For this purpose, it would have been a better approach to inject shHTR4 in the mPFC of the
Emx1-Cre-CK2α but this was not doable due to encountered problems in breeding.
Another possible explanation would be that, even though overexpression of 5-HT4R or upregulation of 5HT4R after CK2 knockdown mediates a strong antidepressant-like response, knockdown of 5-HT4R does
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not lead to depressive-like behavior. Supporting this hypothesis, 5-HT4R KO mice only presented
depressive/anxiolytic-like behavior in certain behavioral paradigms such as reduced time spent in the center
of the open field or decreased sucrose consumption in the SP but did not present any significant phenotype
in NSF, TST and FST. Interestingly, KO mice presented a reduced nesting behavior215 which may indicate
that HTR4 levels, altered in both directions disrupt normal nesting behavior. Furthermore, expression of 5HT4R in different brain regions might be responsible to modulate specific behaviors. In addition, while cotreatment of fluoxetine with a 5-HT4R antagonist, GR125487 abolishes the beneficial behavioral effects of
fluoxetine in mice, administration of GR125487 alone does not facilitate depressive/anxious-like
responses51.
As future experiments, it would be very interesting to study whether knockdown of HTR4 in different areas
relevant for depression research such as the hippocampus, amygdala or basal ganglia would mediate a
depressive-like response in different behavioral tests. Such experiment would provide a good picture of the
role of 5-HT4R in different brain areas and which brain areas are responsible for mediating different mood
related behavioral tasks. Since we were able to partially rescue the depressive-like phenotype in FST of
the Drd1a-Cre-CK2α it would be of great interest to study the response to antidepressants of WT mice
injected with AAV9-shHTR4. Even though knockdown of shHTR4 did not fully mediate a depressive-like
phenotype, mPFC-5-HT4R might be needed to facilitate the therapeutic effect of SSRIS and reduction of
expression may reduce the efficacy of antidepressants. For example, olfactory bulbectomized 5-HT4R KO
mice were unable to respond to chronic fluoxetine treatment 215 and the behavioral effects of fluoxetine in
WT mice were removed when co-administered with 5-HT4R antagonist. 51
Further confirmation that depression did not seem to stem from downregulation of 5-HT4R was that patients
that suffered from MDD had unaltered levels of HTR4, CK2α and CK2β.
After confirming that the mPFC is the region responsible of mediating the antidepressed/anxiolytic-like
phenotype after knockdown of CK2, we wanted to study if modifications in the mPFC would impact the
HPC. Neurogenesis in the DG of the HPC is established as a molecular marker of antidepressant action.
Given the antidepressant-like behavior of floxed mice injected with AAV9-Cre mice or AAV9-HTR4, as well
as the existence of the mPFC–DRN feedback loop resulting in enhanced 5-HT release upon the HPC, we
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studied if these modifications in the mPFC alone would be sufficient to alter the number of adult newborn
neurons in the HPC. In mice, both antidepressants and 5-HT4R partial agonist, RS67333, were able to
increase neurogenesis in a timeframe that coincides with the onset of action of the drugs46. In addition,
MDD is highly correlated with hippocampal-dependent deficits in cognition194,195 and so far, antidepressant
drugs were able to reverse depressive and anxiety symptoms in mice but not cognition deficits 198,199 while
administration of 5-HT4R agonist, RS67333, was able to alleviate cognitive deficits in rodents200
We found that floxed mice injected with AAV9-Cre mice presented increased neurogenesis in the vHPC
and not the dHPC when compared to control animals. This is consistent with the notion that the vHPC is
responsible for regulating emotion and modulating anxiety-like behaviors183,185,206. But interestingly, when
tested in paradigms of spatial learning and working memory, AAV9-Cre mice performed poorer than their
control littermates, AAV9-GFP. Our findings in the AAV9-HTR4 mice were quite different. As opposed to
our expectations, these animals did not present any significant change in neurogenesis in dorsal nor ventral
HPC and did not show any significant cognitive impairment. Based on these results, we could conclude
that HTR4 overexpression in the mPFC did not mediate neurogenesis in the DG of the HPC and most likely,
knockdown of CK2 in the mPFC might regulate another target yet to be identified that would be responsible
for the enhanced neurogenesis in the vHPC as well as the cognition deficits. Whether these two events are
mediated through the same substrate or a different one is unknown. Based on the unexpected results, it
would be very interesting to identify whether this enhanced neurogenesis in the vHPC is required to mediate
the antidepressant-like phenotype. X-Ray ablation in the vHPC of the AAV9-Cre mice would shine some
light to this question. Our hypothesis is that neurogenesis would not be required since we did not observe
such event in the AAV9-HTR4 mice yet they did display a very robust antidepressant and anxiolytic-like
phenotype. It has been shown that neurogenesis was required to mediate the antidepressant effects of
fluoxetine and RS67333 in the NSF paradigm 51. Our HTR4 overexpressing mice presented a reduced
latency to eat in NSF but showed a comparable amount of BrdU+ cells to control mice. Suggesting
enhanced neurogenesis is not required but just the ability to generate newborn neurons.
The lack of fast-acting antidepressants poses a real problem for people suffering from MDD. We are the
first ones to identify CK2 as a novel target mediating an antidepressant-like response in mice. CK2 inhibitors
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have already been tested in clinical trials for cancer treatment and are well tolerated (ClinicalTrials.gov
Identifier: NCT02128282). Nevertheless, due to CK2 ubiquitous expression, it would be unlikely that high
doses of CK2 pharmacological inhibitor will prove to be a successful novel antidepressant drug alone. On
the other hand, our series of experiments involving Drd1a-Cre-CK2α animals treated with fluoxetine or
imipramine showed that absence of CK2 increased responsiveness to antidepressant treatment and it
would be of great interest to test whether co-administration of SSRIs and a low dose CK2 inhibitor will lead
to a faster antidepressant response and, in a similar manner, assess how CK2 inhibitors together with 5HT4R agonist could potentially exert a synergistic effect behavorally in the extent of the antidepressant
response as well as in the onset of therapeutic. Overall, this dissertation provides evidence that protein
kinase CK2 negatively regulates the 5-HT4R in the mPFC both at the transcriptional and the posttranslational level and that this upregulation of the 5-HT4R is responsible for mediating a phenotype
reminiscent of animals chronically treated with antidepressants drugs.
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